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Abstract 
 
 
 
Cutaneous malignant melanoma (CMM) is an aggressive malignancy whose 
incidence and mortality has increased worldwide. CMM is the most common 
cause of death from skin cancer. Wide surgical excision of early stage 
melanoma remains the main curative treatment. Unresectable advanced 
melanoma presents an aggressive behavior, tendency to rapidly metastasize and 
an intrinsic resistance to chemotherapy. The only targeted therapy approved for 
melanoma is vemurafenib, a small molecule targeting BRAF particularly when 
affected by common mutations in the nucleotides encoding for the aminoacid 
V600. These evidences suggest that novel therapeutic options for advanced 
CMM are still required. Melanocytes derive from neural crest cells and 
melanoma cells can express somatostatin receptors (SSTRs) suggesting that at 
least a subgroup of melanomas could have a neuroendocrine differentiation. 
The role of somatostatin (SST) pathway in CMM has been scantly investigated.  
The aim of this project was to evaluate SSTRs expression and to define the 
effects of SST analogs in relation to SSTR protein expression in in vitro 
models of CMM, exploring the role of SST pathway as a potential therapeutic 
target in human CMM. With this propose four cutaneous melanoma cell lines: 
A375, HMCB, COLO38 and M14 were used as in vitro models of CMM. The 
expression of SSTRs was evaluated by retro transcriptase quantitative 
polymerase chain reaction (RT-qPCR) and immunocitochemisty (ICC) in all 
four cell lines. The in vitro effects of daily administration of SST analogs 
pasireotide and octreotide and the BRAF inhibitor vemurafenib on cell 
viability, proliferation and cell cycle were investigated by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) assay, DNA assay and 
fluorescence-activated cell sorting (FACS), respectively. Additionally the in 
vitro effects of daily administration of pasireotide in combination with 
vemurafenib, on cell viability, proliferation and cell cycle were investigated in 
two of the four cell lines (A375 and M14) that resulted sensitive to the effects 
of pasireotide. All tested melanoma cell lines express SSTR mRNA and 
proteins. At mRNA level, SSTR2 was the most expressed receptor followed by 
SSTR1, SSTR3 and SSTR5. The protein expression of SSTR1 was strong in 
A375, COLO38, M14 and moderate for HMCB; protein expression of SSTR2 
was mild for A375 and COLO38, moderate for COLO38 and strong for M14; 
protein expression of SSTR5 was strong for A375 and M14, moderate for 
HMCB and mild for COLO38. The expression of SSTRs by ICC showed a 
predominant cytoplasmic localization in all melanoma cell lines used. 
Moreover, a perinucear staining for SSTR2 in COLO38 cells and for SSTR5 in 
HMCB and COLO38 cells was observed. Pasireotide significantly inhibited in 
a dose dependent-manner viability in A375 and M14 melanoma cell lines 
(maximal effects observed at dose of 10-7M: 41% p<0.01 and 44% p<0.001 vs 
control, respectively). Octreotide significantly inhibited cell viability only in 
A375 cells (maximal effects observed at dose of 10-6M; 54.15% p<0.001 vs 
control). Vemurafenib significantly inhibited A375 cell viability in a dose and 
time-dependent manner (maximal effects observed at dose of 10-6M: 82.89%, 
p< 0.001 vs control). Pasireotide, and vemurafenib but not octreotide 
significantly inhibited cell proliferation in A375 (maximal effects observed at 
dose of 10-6M: 20.57% and 21% p<0.05  vs control, with pasireotide and 
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vemurafenib respectively; IC50  3*10-10M and 2.6*10-8M, respectively) and 
M14 cells (maximal effects observed at dose of 10-6M: 20.57% and 21% 
p<0.05  vs control, with pasireotide and vemurafenib respectively; IC50 3.8*10-
8M and 1.228*10-7M, respectively). Combined treatment with vemurafenib and 
pasireotide had additive inhibitory effects in A375 only on cell viability 
(maximal effects observed at dose of vemurafenib 10-8M + pasireotide 10-9M: 
41.79% p>0.001 vs control). The antiproliferative effects of pasireotide were 
observed only in cell lines presenting a strong SSTR5 protein expression 
(A375 and M14), suggesting that this pattern of SSTR protein expression could 
be predictive of response to this drug in CMM. Preliminary results of the 
FACS analysis suggest that the antiploferative effects of pasireotide in A375 
and M14 could at least in part depend by an inhibition of cell cycle. 
Preliminary results of western blotting experiments, exploring the subcellular 
localization of SSTR2 and 5 in basal condition and after pasireotide or 
octreotide, suggest that the different trafficking of SSTR2 and 5 might explain 
the stronger antiproliferative effects observed with pasireotide compared to 
octreotide in these two melanoma cell lines. In conclusion this study firstly 
described the protein expression of SSTRs and suggested that the 
antiproliferative effects of pasireotide in human cutaneous melanoma cell lines 
could be related to a particular pattern of SSTR protein expression. This study 
has a potential translational value since the expression of SSTRs might indicate 
the potential use of SST analogs, radio-labeled SST analogs, SST analogs 
conjugate with chemotherapic agents and SSTR scintigraphy in the 
management of a subset of patients with CMM. This study encourages further 
studies to better define the role of SST pathway in diagnosis, prognosis and as 
potential target for treatment in human CMM.    
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Introduction 
 
 
 
Cutaneous Malignant Melanoma (CMM) is a potentially lethal form of skin 
cancer, which results from the malignant transformation of melanocytes, which 
are the pigment-producing cells responsible for the colour of skin. Although 
the key triggers leading to malignant transformation of melanocytes have yet to 
be elucidated, they are multifactorial and include UV radiation damage and 
genetic susceptibility. CMM, accounting for 3 to 5 percent of all skin cancers, 
is responsible for approximately 75 percent of all deaths from skin cancers 
(Sladden MJ. et al. 2009, American Cancer Society. 2011). Worldwide, the 
incidence of melanoma continues to rise. The median survival time for 
melanoma patients with metastatic disease is 8-9 months, and the 3-year-
survival rate is less than 15 percent (Balch CM. et al. 2009). Treatment of 
CMM is still a challenge. Conventional chemotherapy with dacarbazine 
(DITC) alone is associated with an objective response rate of, at most, 15 
percent; moreover, nearly all of these responses are partial. Immune-based 
therapies, such as Interferon-α and Inerteleukin-2, have yielded comparable 
response rates, but they are associated with more intense toxicities and no clear 
impact on overall survival (OS) for metastatic melanoma patients (Lui P. et al. 
2007, Eggermont AM. et al. 2009). Over the last decade, significant advances 
have been made in the understanding of  genetic changes that drive melanoma 
development and progression, leading to the authorization of ipilimumab, a 
monoclonal antibody targeting citotoxic T-lymphocytes-associated antigen 4, 
and vemurafenib, a BRAF inhibitor used in patients whose tumors contain a 
V600 mutation in BRAF gene. Results of the BRIM-3 phase III clinical trial 
showed a response rate of 48% and 5% with vemurafenib and DITC, 
respectively, in previously untreated patients with metastatic melanoma 
harbouring V600E mutation. At 6 months, overall survival was 84% in the 
vemurafenib group and 64% in the DITC group. A phase III clinical trial 
reported a median overall survival of 10.0 months among patients receiving 
ipilimumab as compared with 6.4 months among patients receiving placebo 
(Hodi FS. et al.2010). Despite these encouraging data, severe toxicity and 
resistance occur after treatment with these compounds, therefore, new 
treatments for CMM are still required. An alternative targeted approach in the 
management of malignancies is the use of analogs of hormones, whose 
receptors are expressed on tumors and might influence tumor cell proliferation 
(Schally AV and Nagy A. 1999, 2004, Schally AV. 2008). Among them, an 
attractive target for treatment of melanoma and other types of cancers are 
somatostatin receptors (SSTRs). Somatostatin (SST) shows a pleiotropic 
inhibitory effect on cell proliferation and angiogenesis (Ferjoux G. et al. 2000, 
Dasgupta P. 2004, Hejna M. et al. 2002). Consequently, SST synthetic long-
acting analogs have been developed and are currently used in management of 
neuroendocrine tumors (Woltering EA. 1997, Pollak MN and Schally AV. 
1998). The expression of SSTRs on CMM and other melanomas has been 
hypothesized since the 1995, taking into account the neural crest origin of such 
tumors (Williams S. et al. 1997). Therefore in chemoresistant melanoma 
acquiring neuroendocrine phenotype SST analogs might represent an 
alternative treatment. However, the role of SST analogs in CMM is still 
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controversial. SST and its analogs effects are mediated by different G-protein 
coupled receptors (GPCRs) that are differently expressed on normal and 
pathologic tissues. Activation of SSTRs leads to different signalling processes 
through intracellular pathways including Ras/Raf/MAPK (mitogen-activated 
protein kinase) pathway that is classically associated to cell survival and 
proliferation. This pathway seems to be critical to oncogenic signalling in 
melanoma as supported by the existence of driver mutations in genes coding 
for proteins belonging to this pathway. 
 
 
1.1 Cutaneous Melanoma 
 
 
Melanoma is a group of biologically distinct malignancies with heterogeneous 
features including cell of origin, age of onset, ethnic distribution, clinical and 
histologic characteristics, pattern of metastasis and aetiology. Among risk 
factors a causative role of UV radiation, predisposing germ-line alterations, 
mutational processes and patterns of somatic mutations have been identified. 
CMM arises from neoplastic transformation of skin melanocytes. Neoplasms 
are initiated by gain-of-function mutations in oncogenes, which lead to benign 
melanocytic nevi which in turn, due to additional genetic aberrations, progress 
to malignant melanoma.  
 
 
1.2 Epidemiology  
 
 
The incidence of melanoma is continuing to increase worldwide. Once a rare 
cancer, the incidence of malignant melanoma skin cancer in most developed 
countries has risen faster than any other cancer type since the mid-1950s (Hall 
H et al. 1999). CMM is the sixth most commonly diagnosed cancer in the USA 
in both genders (Jemal A. et al. 2006). It is estimated that the annual increase 
in the incidence rate of melanoma has been approximately 3–7 percent per year 
worldwide for Caucasians (Parkin DM. et al. 2001). The estimated lifetime risk 
of an American developing invasive melanoma is 1 in 59 and is projected to 
rise to 1 in 50 by the year 2015 (Fig.1). About the European melanoma 
incidence and mortality, they present differences between European countries, 
possibly related to missed opportunities for early diagnosis and incomplete 
reporting of melanoma in Eastern Europe. The estimated age-standardized 
incidence of melanoma (measured per 100 000 person-years) varies widely 
from 19.2 in Switzerland to 2.2 in Greece calculated by GLOBOCAN (the 
standard set of worldwide estimates of cancer incidence and mortality 
produced by the International Agency for Research on Cancer for 2008). 
Melanoma mortality rates of 1.5 are similar in CEE (Central and Eastern 
Europe) and Western Europe, although rates vary with a high of 3.2 in Norway 
and a low of 0.9 in Greece (Forsea AM. et al . 2012) 
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Figure 1. US invasive melanoma  lifetime risk 
 
 
This increased incidence may be attributable to better and earlier detection of 
melanomas and enhanced public awareness. Patients with deep primary tumors 
or tumors that metastasize to regional lymph nodes frequently develop distant 
metastases. Median survival after the onset of distant metastases is only 6–9 
months, and the 5-year survival rate is less than 5 percent (Houghton AN and 
Polsky D. 2002). An analysis of melanoma trends stratified by thickness, based 
on the Surveillance, Epidemiology and End Results (SEER) registry data from 
1988 to 2006, showed that all four thickness categories (≤1, 1.01–2, 2.01–4 and 
>4 mm) increased in incidence over the 19-year study period (Criscione VD 
and Weinstock MA. 2010). Furthermore, Jemal et al. reported that this increase 
was different by gender; females had a greater increase in thin lesions (4.1 
percent per year) than men, where the increase was greatest in thick 
melanomas (6.1 percent per year) (Jemal A. et al. 2001). Another analysis of 
nine SEER registry databases (1975–2006) showed that age-specific melanoma 
incidence rates were greater among women than men prior to age 40 years at 
diagnosis. In addition, melanomas on the trunk were more frequently 
diagnosed in US men than women, although changes in behavior and life style 
lead to an increase of the incidence of melanomas in the trunk in women over 
the years (Bradford PT. et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
1.3 Melanoma risk factors 
 
 
Risk factors for any malignancy can be subdivided into genetic and 
environmental with interaction between the two (Fig.2). The principal 
established and also postulated risk factors for CMM are:   
 
• Invasive cutaneous melanoma in one or more first-degree relatives; 
• Previous personal primary invasive melanoma; 
• Multiple banal melanocytic naevi (>100); 
• Three or more clinically atypical (dysplastic) naevi; 
• High solar exposure in early childhood (before age 10); 
• Pale Caucasian skin; 
• Red or blond hair; 
• Past history of one or more severe blistering sunburns; 
• Higher socioeconomic group; 
• Past sunbed use, especially before age 30; 
• Occupation (airline crew); 
• Past pesticide exposure. 
 
Approximately 5 percent of all invasive CMM occur in a familial setting with 
two or more close relatives affected. This observation indicates that, in a small 
minority of melanoma patients, low prevalence/high penetrance genes are 
involved. In addition, the typical phenotype of the melanoma patient, with pale 
Caucasian skin, red or blond hair and blue eyes indicates that high 
prevalence/low penetrance genes may interact with environmental factors, 
particularly with sun exposure. 
 
 
 
 
Figure 2. The complex interaction of genetic and environmental factors that concur to 
melanoma development and progression.  
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It has been demonstrated that around one-third of patients in melanoma 
families worldwide have an identifiable germline mutation in CDKN2A, a 
gene important in controlling entry into the cell cycle. A wide range of 
mutations has been reported in these families, with concentration of specific 
mutations in certain geographic areas, such as the Mediterranean, Sweden and 
Scotland, indicating the likely source of the founder mutation (Pho L. et al. 
2006). Functional studies on some of these mutations have indicated that they 
are likely to be a significant causative factor in melanoma development. 
Nevertheless, in more than 50 percent of all families with pathologically 
confirmed invasive CMM no putative responsible gene has yet been identified. 
A number of research groups are currently actively investigating these families 
for new melanoma susceptibility genes. The principal phenotypic risk factor 
for melanoma is Caucasian pale-skinned patient. Furthermore, several studies 
conducted in different countries like Australia (Whiteman DC and Green AC. 
2005), North America (Cho E, Rosner BA and Colditz GA. 2005) and Europe 
(Swerdlow AJ et al. 1986) have all shown that a high count of banal 
melanocytic naevi is a major risk factor for sporadic melanoma. Other 
independent risk factor for sporadic melanoma is the presence of large, atypical 
naevi (dysplastic naevi). Sun exposure plays a primary and supporting role in 
most melanoma tumors. There is evidence that for the four main types of 
CMM, the pattern of excess sunlight exposure which is most damaging varies 
(Habif TP et al. 1996, Ivry GB et al. , MacKie RM. 2006). In the environment 
the ultraviolet (UV) irradiation present in sunlight is the most important 
carcinogen for human skin (Matsumu Y and Ananthaswamy HN. 2004). The 
molecular mechanisms responsible for the carcinogenic effects of UV in 
human skin are various and not fully understood (Situm M et al. 2007). 
Currently, it is thought that the DNA damaging trough the formation of dimeric 
photoproducts and gene mutations, inflammatory, and immunosuppressive 
properties of UVR all contribute to initiation, progression, and metastasis of 
primary melanoma (Garibyan L and Fisher DE. 2010). In particular, UVB 
carcinogenicity is ascribed to the ability of this waveband to induce 
promutagenic DNA lesions, primarily cis-syn cyclobutane pyrimidine dimers 
(CPDs) and pyrimidine(6-4) pyrimidone photoproducts ((6-4)PPs) (Pfeifer et 
al. 2005).  Reactive oxygen species (ROS) overproduction may stimulate 
malignant transformation to melanoma. Photodimeric CPDs and (6-4)PPs can 
induce single C-T or tandem CC-TT transition mutations (Brash et al. 1987, 
Otoshi et al. 2000, Pascucci et al. 1997, Wang et al. 1993), whereas oxidative 
DNA damage can mainly produce various base substitutions and single-strand 
breaks (Moriya. 1993, Shibutani et al. 1991). Changes in ROS signaling 
pathways play also important role in the damaging action of UVA and UVB 
irradiation on the skin. Several studies have also demonstrated that the 
sunburns are strongly related to the development of melanoma (J. M. Elwood 
et al.1985). 
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1.4 Staging of cutaneous melanoma 
 
 
Staging systems for melanoma continue to evolve as our understanding of 
the complex biology of this disease improves. The official guidelines for 
staging melanoma were updated in 2009 by the American Joint Committee on 
Cancer (AJCC) (Balch CM. 2009). This staging system called TNM (tumor-
node-metastasis) is based on the following: the thickness of the tumor (the 
thickness is described using the Breslow scale), whether the tumor 
is ulcerated (has broken the skin), whether the tumor has spread to the lymph 
nodes and if the lymph nodes are joined together, whether the tumor has spread 
to other parts of the body, mitoses within the primary tumor, the site of 
distance metastasis, level of serum of lactate dehydrogenase (LDH) (Fig.3). 
The TNM System is the most widely used system for cancer staging in the 
world. The system defines cancer stage by describing:  
T: the features of the primary tumor. The three distinguishing features are 
tumor thickness, mitoses, and ulceration. Tumor thickness (also known as 
Breslow depth) is measured in millimeters (mm). 
 
1 mm = .04 inch, or less than 1/16 inch  
2 mm = between 1/16 and 1/8 inch  
4 mm = between 1/8 and 1/4 inch  
N: the presence or absence of tumor spread to nearby lymph nodes  
M: the presence or absence of metastasis to distant sites  
 
 
 
 
Figure 3. TNM staging system of melanoma updated by AJCC in 2009. 
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1.5 Molecular biology of melanocytes and their transformation into 
melanoma cells 
 
 
Melanocytes are pigment producing cells of the skin in humans and other 
vertebrates. They constitute a heterogeneous group of cells originating from 
neural crest cells (NCC), capable to produce melanin. Melanocytes are 
predominately localized in the basal layer of the epidermis, however their 
presence in other sides of the body are documented. For this reason other 
functions of melanocytes, a part the production of the pigment melanin, are 
suggested.  Melanocytes seem to have  neuroendocrine functions, they play a 
role in detoxification in the brain, anti-inflammatory activities by reduction and 
binding of ROS in heart and adipose tissue, balance and hearing in inner hear 
and cochlea, hair and eyes pigmentation and protection against UV (Plonka PM 
et al. 2009). They are classically considered the cells of the basal layer of 
epidermis but their presence have also been found in hair, iris, inner ear, 
nervous system, heart , mucosal membrane and central nervous system 
(Tachibana M. 1999, Brito FC et al. 2008). (Fig.4). 
 
 
 
 
Figure 4. Anatomy of the skin, showing the epidermis, dermis, and subcutaneous 
tissue. Melanocytes are in the layer of basal cells at the deepest part of the epidermis. 
 
 
The life cycle of melanocytes consists of several steps including lineage 
specification from embryonic neural crest cells (melanoblasts), migration and 
proliferation of melanoblasts, differentiation of melanoblasts into melanocytes, 
maturation of melanocytes (melanin production in special organelles – 
melanosomes) transport of mature melanosomes to keratinocytes and eventual 
cell death. Proliferation and differentiation of melanocytes during development 
is regulated by numerous genetic and epigenetic factors. Moreover, epigenetic 
factors from the surrounding tissue environment, such as keratinocytes and 
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fibroblasts, the pituitary gland, other organs and the blood supply, as well as 
environmental factors such as ultraviolet (UV) radiation and ionizing radiation 
are also important for the regulation of melanocytes proliferation and 
differentiation. In particular seems that keratinocytes are involved in regulating 
the proliferation and differentiation of melanocytes. In vitro experiments have 
demonstrated that in a culture of proliferating keratinocytes, melanoblasts and 
melanocytes start to proliferate around the keratinocyte colony, suggesting that 
keratinocytes produce and release melanocyte mitogens and melanogen in 
cooperation with basic fibroblast growth factor (bFGF) (Hirobe. 1994). The 
mechanisms leading to malignant transformation of melanocytes are poorly 
understood. In developing malignant melanoma, there is a complex interaction 
of environmental and endogenous (genetic) factors, including: dysregulation of 
cell proliferation, programmed cell death (apoptosis) and cell to cell 
interactions. It has been suggested that several genes involved in melanocytes 
development may also be associated with melanoma cell development (Audrey 
Uong et al. 2010). Even though progress have been made in understanding the 
molecular biology of malignant melanoma, it is still unclear how a normal 
melanocyte becomes a melanoma cell. Many evidences clearly indicate the 
existence of complex molecular machinery that provides checks and balances 
in normal melanocytes. Progression from normal melanocytes to melanoma 
cells is the result of a combination of down- or up-regulation of various 
effectors involved in different molecular pathways. A hypothetical model of 
melanoma development is represented by the  melanoma derived from a pre-
existing nevus, which represent about 25% of all melanoma cases. These 
malignancies develop through a multistep process regulated by a key set of 
genes. Melanocytes must acquire successive genetic abnormalities before they 
get a malignant behavior leading to melanoma formation. The figure 2 shows 
the various stages of melanocytic lesion. In each of these stages a new clone of 
cells acquire growth advantages over the surrounding tissues (Fig.5). In normal 
skin there is an homogeneous distribution of dendritic melanocytes within the 
basal layer of the epidermis. In the early stages, benign melanocytic naevi 
occur with increased numbers of dendritic melanocytes. According to their 
localization, naevi are termed junctional, dermal or compound. Some naevi are 
dysplastic, with morphologically atypical melanocytes. Subsequently, 
melanoma cells begin to growth in a radial mode, this step is called Radial-
growth-phase (RGP) melanoma. This is considered to be the primary malignant 
stage. The final step of progression is the Vertical-growth-phase (VGP) 
melanoma. This is the first stage that is considered to have malignant potential 
and leads directly to metastatic malignant melanoma, the most deadly stage, by 
infiltration of the vascular and lymphatic systems. Pagetoid spread describes 
the upward migration or vertical stacking of melanocytes that is a histological 
characteristic of melanoma. 
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Figure 5. a, Normal skin. b, Naevus. c, Radial-growth-phase (RGP) melanoma. This 
is considered to be the primary malignant stage. d, Vertical-growth-phase (VGP) 
melanoma. (figure from the Article “Melanoma biology and new targeted therapy” of 
Vanessa Gray-Schopfer et al. 2007. Nature) 
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1.6 Molecular bases of CMM  
 
 
CMM is a complex genetic disease in which several altered genes and 
molecular pathways are involved. The clinical heterogeneity of melanoma can 
probably be explained by the existence of distinct types of melanoma with 
different susceptibility to ultraviolet light.  
Cutaneous melanomas, indeed, have four distinct subtypes: 
  
- Superficial Spreading Melanoma (SSM), on intermittently exposed skin; 
- Lentigo Maligna Melanoma (LMM), on chronically exposed skin;  
- Acral Lentiginous Melanoma (ALM), on the hairless skin of the palms and 
soles;  
- Nodular Melanoma (NM), with tumorigenic vertical growth, not associated 
with macular component.  
 
Many studies conducted over several decades on benign and malignant 
melanocytic lesions as well as melanoma cell lines have implicated numerous 
genes in melanoma development and progression. This emerging pattern of 
molecular complexity in melanoma tumors mirrors the clinical diversity of the 
disease and highlights the notion that melanoma, like other cancers, is not a 
single disease but a heterogeneous group of disorders that arise from complex 
molecular changes. Understanding of molecular aberrations involving 
important cellular processes, such as cellular signaling networks, cell cycle 
regulation, and cell death, will be essential for better diagnosis, accurate 
assessment of prognosis, and rational design of effective therapeutics. The 
characterization of molecular signature of individual patient’s lesions could 
provide new insights for selection of a personalized therapy and prediction of 
response to treatment. The principal molecular aberrations affecting 
functionally relevant cellular processes in the oncogenesis of melanoma, such 
as cell cycle control and cell-signaling mechanisms are the following:  
 
 
1.6.1 CDKN2A (Cyclin-Dependent Kinase inhibitor 2A) 
 
 
The best-characterized high-penetrance susceptibility gene predisposing to 
CMM is CDKN2A (N. Ibrahim and F. G. Haluska. 2009, Calder and M. B. 
Morgan. 2010, A. Sekulic et al. 2008). This tumor suppressor gene is located 
on chromosome 9p21 and encodes two distinct tumor-suppressor proteins 
(p14/ARF and p16/INK4a) implicated in the pathogenesis of 25-40 per cent of 
familial CMM. Over 60 different germline mutations in CDKN2A have been 
detected in more than 190 families wordwilde. The majority of these mutations 
are missense mutations in p16CDKN2A (Goldstein AM . et al 2006). To date, 
germline large deletions have been characterised at the 9p21 locus in only six 
families worldwide. A deletion involving CDKN2A exon1a, 2, and 3 and a 
deletion removing exon 1α and half of exon 2 were described in two 
melanoma-prone kindreds, originated from UK and from Norway, respectively 
(Mistry et al. 2005; Knappskog et al. 2006). Large deletions have also been 
found in families with combined proneness to melanoma and nervous system 
tumours (NST): a gross deletion ablating the whole CDKN2A and CDKN2B 
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genes has been reported in a French family (Bahuau et al. 1998; Pasmant et al. 
2007), and a deletion of p14ARF-specific exon 1b of the CDKN2A gene has 
been found in one US family and in two UK families (Bahuau et al. 1998; 
Randerson-Moor et al. 2001; Mistry et al. 2005; Laud et al. 2006).  
 
The p16CDKN2A protein inhibits the activity of the cyclin D1-cyclin-dependent 
kinase 4 (CDK4) complex, that  drives cell cycle progression by 
phosphorylating the retinoblastoma (RB) protein. Thus, p16CDKN2A induces cell 
cycle arrest at G1 phase, blocking the RB protein phosphorylation. RB 
phosphorylation causes the release of the E2F transcription factor, which binds 
the promoters of target genes, stimulating the synthesis of proteins necessary 
for cell division. Normally the RB protein prevents the cell division. When the 
RB protein is absent or inactivated by phosphorilation, there is a promotion of 
the cell cycle progression (Pacifico A. and Leone G. 2007). 
 
p14CDKN2A stabilizes p53, interacting with the Murine Double Minute (MDM2) 
protein, whose principal function is to promote the ubiquitin-mediated 
degradation of the p53 tumor suppressor gene product (Stott FJ. et al. 1998, 
Tsao H. et al. 2000, Piepkorn M. 2000). The p53 protein arrests cell division at 
G1 phase to allow DNA repair or to induce apoptosis of potentially 
transformed cells. In normal conditions, the expression levels of p53 in cells 
are low. In response to DNA damage, p53 accumulates and prevents cell 
division. Therefore, inactivation of the TP53 gene results in an accumulation of 
genetic damage in cells which promotes tumor formation. In melanoma, the 
frequency of TP53 mutations is low (Box NF and Terzian T. 2008). Different 
signals regulate p53 levels by controlling its binding with MDM2. Several 
kinases play this role, catalyzing stress-induced phosphorylation of serine in 
the trans-activation domain of p53. Moreover, several proteins, including E2F, 
stabilize p53 through the p14CDKN2A-mediated pathway. 
Data obtained from genetic and molecular studies over the past few years have 
indicated that the CDKN2A locus as the principal and rate-limiting target of 
UV radiation in melanoma formation (Goldstein AM. et al. 2005). 
 
 
1.6.2 CDK4 (Cyclin-Dependent Kinase-4) 
 
 
It represents another high-penetrance melanoma susceptibility gene. Only three 
melanoma families worldwide are carriers of mutations in CDK4 (Arg24Cys 
and Arg24His) (K.D. Meyle and P. Guldberg. 2009). Located on chromosome 
12q14, CDK4 encodes cyclin-dependent kinase 4 protein, a constituent of the 
complex CDK4/6. The Arg24Cys makes the p16CDK2NA protein unable to 
inhibit the D1-ciclyn-CDK4 complex, resulting in a sort of oncogenic 
activation of CDK4. 
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1.6.3 RAS/RAF/MEK/ERK Signaling Pathway: the role of BRAF in 
melanoma 
 
 
Among the signaling pathways that are constitutively activated in melanoma, 
mitogen-activated protein kinase (MAPK) pathway has been considered one of 
the most attractive targets for treatment (Satyamoorthy et al. 2003, Sharma et 
al. 2006, Smalley et al. 2006, Solit et al. 2006). This pathway represents the 
major signaling cascade involved in the control of cell growth, survival, 
proliferation and migration and it seems to be implicated in rapid melanoma 
growth, enhanced cell survival and resistance to apoptosis playing a major role 
in both development and progression of melanoma and seems (Davies H. et al. 
2002, MMMP). When active in its GTP-bound state, RAS activates a number 
of downstream effectors, one of which is the RAF family of serine/threonine 
kinases. There are three isoforms of RAF, namely, A-Raf, BRAF, and CRAF 
(also called Raf-1). Once activated, RAF stimulates the MAPK cascade, 
resulting in the sequential activation of MEK1 and MEK2, which in turn 
activates ERK1 and ERK2 (Crews et al. 1992; Kyriakis et al. 1992). Once 
activated, the ERKs either activate cytoplasmic targets or migrate to the 
nucleus, where they phosphorylate transcription factors. 
In melanocytes, the MAPK pathway is activated by growth factors released 
from the local microenvironment and through receptor tyrosine kinases 
activation. Under physiological conditions, these growth factors only induce a 
weak stimulation of the MAPK pathway that is insufficient to induce 
melanocyte proliferation. In most melanoma cells, the situation is very 
different and it has been shown that >90 per cent of clinical melanoma 
specimens have continuous hyperactivity in the MAPK pathway (Cohen et al. 
2002). Although MAPK activity in melanoma cells can arise through autocrine 
growth factor stimulation (Nesbit et al. 1999), N-cadherin-based homotypic 
cell–cell adhesion (Li et al. 2001), and melanoma cell–matrix adhesion, it is 
more commonly activated after the acquisition of an activating oncogenic 
mutation.The first such MAPK-activating mutation to be reported in melanoma 
was in NRAS (Padua et al. 1984). Mutations in NRAS have since been 
identified in 15–20 per cent of all melanomas, and are most commonly the 
result of the substitution from leucine to glutamine at position 61. 
The most common mutation to be reported in melanoma thus far is in BRAF, 
the serine–threonine kinase located downstream of NRAS. In fact, 
approximately 50 per cent of melanomas harbor activating BRAF mutations. 
Among the BRAF mutations observed in melanoma, over 90 per cent are at the 
codon 600, and among these, over 90 per cent are a single nucleotide mutation 
resulting in a substitution of a glutamic acid to a valine (BRAF V600E: 
nucleotide 1799 T>A; codon GTG>AAG). The second most common mutation 
is BRAF V600K substituting lysine for valine, that represents 5-6 per cent 
(GTG>AAG), followed by BRAF V600R (GTG>AGG), an infrequent two-
nucleotide variation of the predominant mutation, BRAF V600 ‘E2’ 
(GTG>GAA), and BRAF V600D (GTG>GAT) (Catalogue of Somatic 
Mutation in Cancer, COSMIC). The  BRAF V600E mutation  activates BRAF 
and induces constitutive MEK-ERK signaling in cells (Davies H. et al. 2002, 
Wan PT. et al. 2004) (Fig.6). The presence of BRAF mutations in nevi strongly 
suggests that BRAF activation is necessary but not sufficient for the 
development of melanoma.  Acquisition of BRAF V600E mutation seems to be 
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an early event in melanoma development, moreover BRAF mutations occur at 
high frequency in melanomas that are strongly linked to intermittent sun 
exposure. BRAF V600E has been implicated in different mechanisms of 
melanoma progression, and principally, in addition to the MAPK pathway 
activation, evasion of senescence and apoptosis, unchecked replicative 
potential, angiogenesis. No clear differences in prognosis were noted between 
BRAF-mutated versus wild-type melanomas. Features of the  antecedent 
primary melanoma significantly associated with BRAF mutation were the 
superficial spreading and nodular hisopatological subtypes, the presence of 
mitoses, the presence of occult primary melanoma, a truncal location and the 
age at the diagnosis of the primary tumor (<50 years). 
 
 
 
 
Figure 6. Oncogenic BRAF signaling pathway 
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1.6.4 PTEN (phosphatase and tensin homolg) and PI3K/AKT Pathway 
 
 
Among the other mutated genes and pathways that may be equally important 
for melanoma development and progression there are the PTEN gene and 
PI3/AKT pathway. Activation of PI3/AKT pathway in melanoma occurs 
through either paracrine/autocrine growth factors or less of expression and/or 
mutation of negative pathway regulators (PTEN). In particular, the insuine-like 
growth factor-I is known to aid the growth of early stage melanoma cells, at 
least in part, through the activation of PI3/AKT pathway (Satyamoorthy et al. 
2002). Activation of AKT pathway stimulates cell cycle progression, survival, 
metabolism and migration through phosphorylation of many physiological 
substrates (Stokoe D. 2001, Dania PL. 2000, Kandel ES and Hay N. 1999, 
Downward J. 2004). It has been proposed that a common mechanism of 
activation of AKT is DNA copy gain involving  the Akt3 locus, which is found 
in 40-60 per cent of melanomas (it leads to a selective constitutive activation in 
AKT3). AKT expression strongly correlates with melanoma progression, and 
depletion of AKT3 induces apoptosis in melanoma cells and reduces the 
growth of xenografts (Staal SP. 1984, Stahl JM. et al. 2004). One of the most 
critical regulator of AKT is PTEN, that degrades the products of PI3K, thereby 
preventing the activation of AKT. However, the mechanism by which PI3K 
pathway is activated in melanoma remains not fully elucidated, but may 
involve the loss of expression or functional inactivation of PTEN (Fig.7). 
 
 
 
Figure 7. Schematic of the canonical Ras effector pathways Raf-MEK-ERK and 
PI3K-Akt in melanoma.  
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1.6.5 mTOR (mammalian target of rapamycin) pathway 
 
 
Another signaling cascade intimately linked to the PI3K/AKT pathway and 
whose hyperactivation is involved in melanoma pathogenesis, is the mTOR 
pathway. mTOR signaling involves the activity of two signaling complexes, 
mTORC1 and mTORC2. Increased activity in these two downstream pathway 
components leads to increased protein translation and cell proliferation (Fig.8). 
The two different mTORC complexes have opposite effects on AKT signaling, 
with mTORC1 suppressing AKT signaling and mTORC2 directly activating 
AKT through a phosphorylation event at Ser473 (Sarbassov et al. 2004). There 
is also evidence that mTORC1 inhibition may lead to increased PI3K/AKT 
signaling through the upregulated expression of the insulin-like growth factor-I 
adaptor protein IRS2 (Tamburini et al. 2008). mTOR signaling is known to be 
active in melanoma, with immunohistochemical studies showing the 
constitutive phosphorylation of p70 S6 kinase in a panel of metastatic 
melanoma samples (Karbowniczek et al. 2008). Furthermore, results from 
other groups also indicate that the activation of mTOR pathway is related with 
MAPK pathway activation in melanoma. Some evidences suggest that the 
mTOR pathway activation seems to be associated with worse prognosis, 
especially in conjunctival melanomas. Overall, the alterations in major 
components of the MAPK, such as BRAF and NRAS mutations, and mTOR 
pathways, PTEN  loss and AKT overexpression, seem to have substantial 
influence in melanoma progression, being both pathways linked to survival and 
chemoresistence in melanoma (Guertin DA. et al. 2007). 
 
 
 
Figure 8. Schematic representation of mTOR pathway. The two best-characterized 
mTORC1 substrates, elongation factor 4e-binding protein 1 (4e-BP1) and ribosomal 
protein S6 kinase-1 (S6K1), are components of the translational control machinery and 
mediate cap-dependent translation and ribosome biogenesis, respectively. 
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1.6.6 MITF (microphthalmia-associated transcription factor) 
 
 
Increased interest has been focused on the activity of the microphthalmia-
associated transcriptor factor (MITF), which is considered to be the "master 
regulator of melanocytes" since it seems to be crucial for melanoblast survival 
and melanocyte lineage commitment. MITF, in addition to its involvement into 
the differentiation pathways such as pigmentation, may play an important role 
in the proliferation and/or survival of developing melanocytes, contributing to 
melanocyte differentiation by triggering cell cycle exit. The differentiation 
functions of MITF are displayed when the expression levels of this protein are 
high. Indeed, high MITF levels have been demonstrated to exert an anti-
proliferative activity in melanoma cells (Wellbrock C and Marais R . 2005). In 
this regard, low levels of MITF protein were found in invasive melanoma cells 
(Hoek KS. et al. 2008) and have been associated with poor prognosis and 
clinical disease progression (Salti GI- et al. 2000). 
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1.7 Current therapies for CMM 
 
 
Melanoma is an extremely aggressive disease with high metastatic potential 
and a notoriously high resistance to citotoxic agents. This is thought to be 
because melanocytes originate from highly motile cells that have high 
enhanced survival properties. Melanoma cells have low levels of spontaneous 
apoptosis in vivo compared with other tumor cell types, and relatively resistant 
to drug-induced apoptosis in vitro (Soengas M. and Lowe S. 2003). There are 
several approved postoperative adjuvant therapies for malignant melanoma like 
chemotherapy (dacarbazine, DTIC) and immunotherapy (Interferon-a, 
interleukin-2, ipilimumab). 
 
 
1.7.1 Chemotherapy 
 
 
DTIC: Chemotherapy continues to be an important tool in the treatment of 
melanoma. While not having demonstrated an overall survival benefit, 
chemotherapy has a clear role for palliation of patients with melanoma (Lee 
SM. 1995). Multiple chemotherapeutics have been evaluated in the treatment 
of advanced melanoma however only DTIC has been approved for use by the 
Food and Drug Administration (FDA). DTIC, and the analog drug 
temozolomide, are alkylating agents that damage DNA by introducing alkyl 
groups to guanine bases, eventually cell death via apoptosis and other cell 
death mechanisms. DTIC has become the “standard of care” benchmark for the 
treatment of metastatic melanoma. However, the drug has never been shown in 
a randomized phase III trial to improve overall survival. Generally, DTIC is 
associated with a response rate of approximately 10–20 per cent and a 
progression-free survival of approximately three to six months (Crosby T. et al. 
2000). The side effect profile of DTIC is predominately dictated by nausea, 
vomiting and bone marrow suppression in the form of leucopenia and anemia. 
In a phase III trial of 305 patients, temozolomide (TMZ) was not found to be 
significantly more efficacious as compared to DTIC in terms of overall 
survival (OS), 7.7 versus 6.4 months, respectively, and progression-free 
survival (PFS), 1.9 months versus 1.5 months, respectively (Middleton MR. et 
al. 2000). A second phase III trial of TMZ versus DTIC in 859 patients 
confirmed this, showing no difference in OS, 9.1 versus 9.4 months or PFS, 2.3 
versus 2.2 months, respectively) (Patel PM et al.2001). Despite various 
attempts to improve the efficacy of TMZ, it remains approximately that of 
DTIC. The major advantage of TMZ is the ease of dosing given the oral 
formulation of the drug. Despite this advantage, TMZ has not achieved FDA 
approval for the treatment of metastatic melanoma.Others classes of alkylating  
and cytotoxic agents with documented activity in melanoma are nitrosoureas, 
microtubule disrupting agent, taxanes and platinum. However, none of these 
agents has been approved by the FDA for treatment of advanced melanoma, 
except fotemustine that has been approved by some European regulators.Most 
chemotherapeutic drugs function by inducing apoptosis in malignant cells, so 
resistant to apoptosis is likely to underlie drug resistance in melanoma, and this 
extraordinary resistance to chemotherapy, radiotherapy and immunotherapy is 
a major barrier to successful treatment of melanoma. On the basis of these 
27 
 
principles, several new targeted agents are currently being evaluated and tested 
alone or in combination with conventional chemotherapy. 
 
 
1.7.2 Targeted therapies in melanoma 
 
 
The identification of activating mutations in melanoma, combined with a 
growing appreciation of the different pattern of genetic changes in the 
anatomically defined melanoma subtypes, has become the focus of a concerted 
effort to translate these discoveries into personalized therapeutic approaches 
for melanoma. Novel ways to modulate the immune system by monoclonal 
antibodies as well as various signalling pathway inhibitors are responsible for 
creating a whole new therapeutic landscape. Several novel targets are currently 
being investigated in melanoma. The increasing of knowledge of the molecular 
alterations associated with melanoma progression provides rational druggable 
targets for development of novel therapeutic strategies, including alterations in 
key intracellular signalling pathways and growth factor receptors. 
BRAF inhibitors: A number of BRAF inhibitors are currently under clinical 
development and evaluation. Sorafenib (BAY43-9006, Bayer) is a bi-aryl urea 
small molecule broad-spectrum kinase inhibitor. It is able to inhibits the 
vascular endothelial growth factor receptor (VEGFR) and RAF kinase, which 
also has activity against C-Kit and platelet derived growth factor receptor beta 
(PDGFR-β). Activity against melanoma was demonstrated in phase I studies, 
and so it was further developed for this indication in combination with the 
usual combination of carboplatin and paclitaxel. The response rate in phase I 
trial was over 30 per cent, and so it was evaluated also in phase II and III trials 
that moreover failed. The addition of sorafenib to carboplatin and paclitaxel did 
not improve any of the relevant end points over placebo in  advanced 
melanoma patients. Studies of sorafenib indicate that it lacks of selectivity and 
potency for RAF, and it is highly potent inhibitor of VEGFR2, VEGFR3, and 
several other kinases (Wilhelm SM. et al. 2004). 
 
Vemurafenib (PLX3042): Vemurafenib is a potent and specific inhibitor of 
BRAF with the V600E mutation (Fig.9). It has marked antitumor effects 
against melanoma cell lines with the BRAF V600E mutation only. It is inactive 
in the cell lines with wild type BRAF (Flaherty KT, et al. 2010). Flaherty et al. 
conducted a Phase I and II trials for vemurafenib study in patients with 
unresectable, previously untreated stage IIIC or stage IV melanoma that tested 
positive for the BRAF V600E mutation. A phase I trial established the 
maximum tolerated dose to be 960 mg twice daily which showed responses 
against the tumor. A phase 2 trial involving patients who had received previous 
treatment for melanoma with the BRAF V600E mutation displayed a confirmed 
response rate of 53 per cent, with a median duration of response of 6.7 months. 
The levels of phosphorylated extracellular signal- regulated kinase (ERK), 
cyclin D1, and Ki-67 were markedly reduced at day 15 as compared with 
baseline in all specimens examined. This study proposed that vemurafenib 
inhibited the MAP kinase pathway, resulting in decreased cyclin D1 levels and 
decreased proliferation. Subsequently, Phase III trial was conducted in 680 
patients with previously untreated, unresectable stage IIIC or stage IV 
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melanoma with BRAF V600E mutations. The patients were randomized to 
vemurafenib or DTIC (Guo J, et al. 2011). There was an increase in median 
survival from 8 months for DTIC to 12.3 months for vemurafenib (Chapman 
PB. et al. 2011). A total of 672 patients were evaluated for OS. At 6 months, 
OS was 84 per cent in the vemurafenib group compared to 64 per cent in the 
DTIC group. Estimated median progression-free survival (PFS) in the 
vemurafenib group and in the DTIC group was 5.3 months and 1.6 months 
respectively. The most common adverse events in the vemurafenib group were 
cutaneous events, arthralgias, and fatigue; photosensitivity skin reactions of 
grade 2 or 3 were seen in 12 per cent of the patients. Among patients treated 
with vemurafenib, 18 per cent were reported to have at least one squamous-cell 
carcinoma of the skin or keratoacanthoma.  Vemurafenib displayed a relative 
reduction of 63 per cent in the risk of death and of 74 per cent in the risk of 
tumor progression in untreated, unresectable stage IIIC or stage IV melanoma 
with the BRAF V600E mutation, in comparison with treatment with DTIC. 
Vemurafenib 960 mg, orally administered twice daily was approved by FDA in 
2011 to treat patients with metastatic or unresectable melanoma. 
 
 
 
 
Figure 9.  The structural formula of vemurafenib 
 
 
Currently, several other studies are ongoing for the evaluation of different 
classes of BRAF inhibitors: dobrafenib that is a selective kinase inhibitor that is 
active against several mutated forms of BRAF kinase including BRAF V600E, 
BRAF V600K, and BRAF V600D or Trametinib that reversibly and selectively 
inhibits the activation of mitogen-activated extracellular signal regulated kinase 
(MEK) 1 and MEK2 and inhibits their kinase activity. 
 
 
1.7.3 Immunotherapy 
 
 
Ipilimumab: Melanoma is characterized as one of the most immunogenic 
tumors due to the presence of tumor infiltrating lymphocytes in resected 
melanoma, occasional spontaneous regressions, and clinical responses to 
immune stimulation. The immunogenicity of melanoma has led investigators to 
study novel immune strategies to overcome tumor immune evasion. One 
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mechanism by which T cells self-regulate their activation is through expression 
of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 functions 
as a negative co-stimulatory molecule for the T cell, and therapies that 
antagonize CTLA-4 remove the brakes from the T cell leading to a net effect of 
T cell hyper-responsiveness. In march 2011 FDA approved the cancer 
immunotherapy drug ipilimumab (yervoy) for metastatic melanoma patients. 
Ipilimumab is human IgG1 monoclonal antibody that blocks CTLA-4, thereby 
increasing T-cell activity and promoting antitumor activity. Two phase 3 
randomized clinical trials have evaluated ipilimumab in metastatic melanoma. 
In the first trial of patients with previously treated unresectable stage III or IV 
melanoma, ipilimumab demonstrated an improved overall survival versus 
glycoprotein 100 peptide vaccine (gp100) (10.1 vs 6.4 months) (Robert C. et al. 
2011). In the second phase 3 trial in previously untreated patients with 
metastatic melanoma, ipilimumab plus DTIC demonstrated improvement in OS 
versus single agent DTIC (11.2 vs 9.2 months. In both phase 3 studies, the 
response rate, complete response (CR) and partial response (PR) was only 10 
per cent to 15 per cent and the disease control rate (CR, PR, and stable disease 
(SD) was approximately 30 per cent. In addition, the improvement in percent 
of patients alive at one and two years is consistently 10 per cent better than the 
non-ipilimumab containing arms. While the response rate and improvement in 
OS in ipilimumab is relatively modest, the toxicities of the therapy, including 
immune-related enterocolitis, hepatitis, and dermatitis, are highly manageable. 
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1.8 Neuroendocrine differentiation of melanoma cells 
 
 
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms which 
take origin from the neuroendocrine cell system and are characterized by 
embryological, biological and histopathological differences. Traditionally 
considered as a rare and "niche" pathology, over the last decades they have 
gained significant attention from the scientific community, even because of 
their increasing incidence and prevalence probably imputable to the availability 
of more sensitive diagnostic tools and to the development of higher awareness 
among clinicians. However, commonly, neuroendocrine tumors seem to be 
characterized by the secretion of specific markers (for example Chromogranin, 
synapsin…)  and a distinctive pattern of receptors expression. The term 
"neuroendocrine" has been used to define the phenotype of cells that secrete 
their products in a regulated manner, in response to a specific stimulus. 
Neuroendocrine features have been used as evidence of a common 
embryological origin for normal and neoplastic cells. However, it is now 
recognized that neuroendocrine characteristics can be observed in various cell 
types that do not have a common embryological origin with neurons and 
endocrine cells. Although melanoma is  not commonly classified as 
neuroendocrine tumor, some subtypes of melanoma can exhibit a 
neuroendocrine phenotype. Moreover, another feature of melanoma as 
neuroendocrine tumor is the expression of SST receptors (SSTRs), G protein-
coupled receptors with inhibitory capacity growth, proliferation and secretion 
in some NETs. Although the evaluation of the distribution of SSTRs by 
imaging with 111In-pentetreotide scintigraphy (OctreoScan) has limited 
sensitivity for localizing melanomas, tumors that can be imaged by OctreoScan 
may be amenable to adjuvant therapy with octreotide or targeted therapy with 
high-energy radioisotope-labeled octreotide (Sharon S. Lum. 2001). In 2005, 
Eyden B. et al., demonstrated, by immunohistochemistry experiments(IHC) , 
that malignant melanoma showed a neuroendocrine differentiation. In addition 
to expression of typical melanoma markers such as S100 protein, HMB-45 and 
melan-A, melanoma cells may be shown to express a range of neuroendocrine 
markers, including synaptophysin, chromogranin, neurofilament protein, 
CD56, VIP and GFAP. Ultrastructure may reveal typical membrane-bound 
neurosecretory granules (Eyden B. 2005, Banerjee SS. And Eyden B. 2007). 
However, the knowledge about the “neuroendocrine” aspects of melanoma 
cells are sill poor and further studies are required.  More than 15 years ago, it 
has been proposed for the first time that melanocytes are the sensory and 
regulatory cells with computing and amplifying capabilities, which detect and 
transform external and/or internal signals/energy into organized regulatory 
network(s) for the maintenance of the cutaneous homeostasis. This concept is 
in agreement with a hypothesis that melanocytes are ‘neurons of the skin’ 
formulated by Aaron B. Lerner. Melanocytes produce classical stress 
neurotransmitters, neuropeptides and hormones, and that this production is 
stimulated by ultraviolet radiation, biological factors and other agents that act 
within the skin neuroendocrine system. Furthermore, their production is not 
random, but hierarchical and follows the structures of classical neuroendocrine 
organizations such as hypothalamic-pituitary-adrenal axis, serotoninergic, 
melatoninergic and catecholaminergic systems. An example of an intrinsic but 
overlooked neuroendocrine activity is production and secretion of 
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melanogenesis intermediates including L-DOPA or its derivatives that could 
enter circulation and act on distant sites. Such capabilities have defined 
melanocytes as neuroendocrine cells that not only coordinate cutaneous but 
also can affect a global homeostasis. 
 
 
1.8.1 Somatostatin and cancer 
 
 
Somatostatin, SST (also known as growth hormone-inhibiting hormone 
(GHIH) or somatotropin release-inhibiting factor (SRIF) is a peptide hormone 
that regulates the endocrine system and affects neurotransmission, cell 
proliferation and numerous secondary hormones release inhibition. Two active 
biologically forms derive from the C-terminus portion of a single pro-peptide: 
SST-14 and SST-28. SST acts on its multiple cell targets via a family of six 
receptors that originate from five genes: SSTR1, SSTR2a, SSTR2b, SSTR3, 
SSTR4, SSTR5. SSTR2 is alternatively spliced at its C-terminus producing the 
SSTR2a and the SSTR2b variants that have a somewhat different tissue 
distribution. Besides their expression in normal tissues, SSTRs have been 
identified in tumor cell of different aetiology including pituitary, pancreatic, 
breast and hematopoietic tissues. Moreover, the majority of human tumors do 
express SSTRs, often more than one receptor subtype (Hofland, L.J. and S.W. 
Lamberts. 2001). As mentioned above, the SSTRs are members of the G-
proteins coupled receptors (GPCRs) superfamily and so modulate cellular 
function through multiple pathways coupled to G-protein dependent signalling 
pathways. The different signaling pathways activated by the various SSTRs 
subtypes vary according to the receptor subtype and tissue localization. 
However, all SSTRs subtypes inhibit Adenylate Cyclase and cAMP production 
upon ligand binding (Patel, Y.C. 1999). All of the pleiotropic effects of SST in 
the different target tissues can be explained by two basic biological 
mechanisms: inhibition of secretion and inhibition of proliferation. As already 
mentioned, the SST peptides inhibit secretion (of neurotransmitters or 
hormones) from cells in different tissues such as the pituitary gland, the 
endocrine pancreas and the stomach. The molecular mechanism by which SST 
exerts its inhibitory effects on cell secretion, is still a matter of intense study 
and may vary between the different cell types. However, it is generally 
accepted that after binding its receptors, SST or SST analogs, active an 
intracellular trasductional message that downregulates the enzyme Adenilate 
Cyclase, which in turn inactives Protein Kinase A (PKA), leading to an 
intracellular decrease of both cAMP and Ca2+. As reported by literature this 
signalling is mainly responsible for the secretion inhibition, with some effects 
due to the activation of phosphatases such as calcineurin (Bousquet, C. et al. 
2001). Another intracellular pathway activated by this neuropeptide, in fact, 
shows the upregulation of some phosphatases belonging to different families 
such as serin-threonin kinases (PTPases, SHP-1 and SHP-2). SST and its 
analogs also exert antitumor activity through direct and indirect mechanisms, 
acting through SSTRs, which are found on tumor cells and cells in the tumor 
microenvironment (Fig.10). 
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Figure 10. Antitumor effects of SST analogs. SST analogs exert antitumor activity 
through both direct and indirect mechanisms through SSTRs.  
 
 
The direct anti-proliferative effects of SST and SST analogs are largely 
believed to be due to the activation of tyrosine phosphatases that 
dephosphorylate (and inhibit) growth factor receptors. In addition, the SST-
mediated activation of phosphatases regulates more distal signalling pathways 
such as the MAPK pathway. Addition of SST (or synthetic analogs) to SSTRs 
expressing proliferating cells usually produces cell growth arrest at the G1 
phase of cell cycle (Benali, N., et al. 2000). Interestingly, in some cells, 
activation of the SSTR2 and SSTR3 subtypes induced apoptosis and cell death 
rather than growth arrest through activation and upregulation of the tumor 
suppressor p53 and the pro-apoptotic protein Bax (Sharma, K. and C.B. 
Srikant. 1998). In fact, the expression of SSTRs in several human tumors was 
so pervasive that it helped to create an entire new field in oncology: peptide 
therapy. SST analogs have also been used in direct tumor reduction with 90Y 
radiolabeled analogs and in the symptomatic treatment of hormone secreting 
tumor (Reubi, J.C. 2003, Kaltsas, G.A. et al. 2005). Indirect antitumor effects 
of SSAs result from suppression of the secretion of growth or angiogenic 
factors. Angio-inhibitory action of SSTR2 in tumors (such as pancreatic 
cancer) involves the upregulation of the expression of thrombospondin-1 (TSP-
1), a potent antiangiogenic factor. TSP-1 inactivates the angiogenic effects of 
VEGF and therefore plays a crucial role in SSTR2 tumor-suppressive activity 
on pancreatic tumor growth (Bevan, J.S. 2005) (Fig 11). 
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Figure 11. Mechanisms of antitumor activity of synthetic SST analogs in 
neuroendocrine tumors (NET).  
 
 
After agonist activation, GPCRs are phosphorylated (involving protein kinase 
A, protein kinase C, and GPCR kinases) and internalized, probably via the 
formation of clathrin-coated pits (involving β-arrestins). The internalized 
receptors are then directed to endosomes in which they are dephosphorylated. 
Subsequently, the receptors are recycled back to the plasma membrane as 
functional (resensitized) receptors. GPCR downregulation results from 
lysosomal degradation of intracellular receptors, decreased mRNA 22 and 
receptor protein synthesis, as well as increased degradation via mobilization of 
membrane receptors directly to the lysosomal compartment (Jacobs S. and S. 
Schulz. 2008, Tulipano G. et al. 2004, Liu Q. et al. 2005). Actually, the 
presence and the role of SSTRs in CMM is not yet clarified because 
controversial results on SSTRs expression and the anti-proliferative effects of 
SST analogs in melanoma have been obtained.  
Early in 1995, was hypothesized that malignant melanoma, being of neural 
crest origin, might contain SSTRs (Williams S. et al. 1997). The following 
effective finding that some melanoma contain SSTRs confirm that some 
subtypes of melanoma present neuroendocrine feature and implies some host 
control of melanoma growth. M Martinez-Alonzo et al. evaluated the SSTRs 
expression in 18 human skin melanoma cell lines. Their results, in agreement 
with previous studies, showing that SSTR2 is the most abundantly expressed 
SSTR in the majority of tumor types (Hofland Lj et al. 2001) and in cutaneous 
and uveal melanoma too (Navid Ardjomand et al. 2003, Lum SS. et al. 2001, 
Hofland Lj et al. 2001). They also test the effects of two SST analogs, 
octreotide and pasireotide (SOM230), on cell proliferation. The SAs 
investigated in this study, did not, however, significantly inhibit melanoma 
growth or induce cell death. Since the generally reported high expression of 
SSTRs in neuroendocrine tumors (NET), SAs have a pronounced role in the 
medical therapy for this class of tumors, especially pituitary adenomas and 
well-differentiated gastroentero pancreatic NET (GEP NET). The findings of 
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SSTRs  in melanoma, lead to hypothesize the use of SAs could as a new 
possible promising  therapeutic approach for this aggressive skin cancer. A 
deeper knowledge of the involvement of somatostatinergic system in 
melanoma may shed new light on the potential role of SSTRs as targets for 
adjuvant biotherapy in patients with advanced melanoma. On the basis of this 
evidence, the pourpose of the  current study is the evaluation of SSTRs 
expression in cutaneous melanoma cell lines and investigating the role of SST 
analogs, particularly the pan-SSTRs agonist (pasireotide), as potential 
treatment in preclinical models of  melanoma. 
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Aim of the Thesis 
 
The incidence of CMM increased over time and current therapies produced 
disappointing results because of intrinsic tumor resistance and/or relapse due to 
a progressive escape. Therefore, oncogenesis of CMM need to be better 
addressed, in order to develop new treatment strategies.  
Melanocytes originate from neural crest and can express SSTRs, suggesting a 
neuroendocrine features for some subgroups of CMM (Diakatou, E. et al. 2011, 
de Bruin C. et al. 2009), as most of neuroendocrine tumors. Given the 
neuroendocrine differentiation of some CMM, these tumors might be 
responsive to treatment with SST analogs. The rational to treat melanoma with 
SST analogs, alone or in combination with the BRAF inhibitor vemurafenib, is 
based on the well-known evidence that both drugs target the MAPK pathway, 
which has a critical role in melanoma development and progression, thus 
representing a primary therapeutic target. SST analogs, by binding SSTRs via 
interaction with Gi proteins, are able to inhibit adenyl cyclase (AC) activity 
and phosphatidylinositol metabolism, and to modulate MAPK pathway. This 
process results in anti-secretive effects in endocrine cells, as well as in 
increased apoptosis and inhibition of cell growth (Theodoropoulou M. et al. 
2013.) On the other hand, vemurafenib is able to suppress the constitutive 
activation of MAPK pathway in melanoma cells harboring BRAF mutations. 
Therefore, the current study aimed at: 
1. better understanding the role of SST analogs and SSTRs in in vitro models 
of CMM; 
2. evaluating the expression of SSTRs in four CMM cell lines (A375, HMCB, 
M14 and COLO38); 
3. investigating the in vitro effects of SST analogs pasireotide and octreotide, 
alone or in combination with vemurafenib, on cell viability, proliferation 
and cell cycle.  
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MATERIALS AND METHODS 
 
 
 
3.1 Study methodology  
 
 
In this study, we characterized the expression of SSTRs in four different 
human melanoma cell lines: A375, HMCB M14 and COLO38. The gene and 
protein expression and the intracellular localization of these receptors was 
explored. In all cell lines we tested the dose and time-dependent effects of the 
BRAF inhibitor (vemurafenib) and two SST analogs (pasireotide and 
octreotide) on cell viability. The effects of these drugs, alone or in combination 
on cell proliferation and cell cycle were explored. 
 
 
3.2 Cell Lines and Culture Conditions 
 
 
The human melanoma cell lines A375 and HMCB were purchased from 
American Type Culture Collection ATTC (Manassas, VA, USA) and  
COLO38 and M14 were kindly provided by Department of Oncological 
Immunology, Istituto Nazionale per lo Studio e la Cura dei Tumori 
"Fondazione Giovanni Pascale"-IRCCS-ITALIA, Naples, Italy. The HMCB 
cells were maintained in Minimum Essential medium and A375, COLO38 and 
M14 were cultured in Dulbecco’s Modified Eagle Medium (MEM D-MEM 
GIBCO® Cell Culture Invitrogen.com) with non-essential amino acids, 10% 
Fetal bovine serum (FBS, Invitrogen Life Technologies, Carlsbad, CA, USA), 
0,5 µg/ml amphotericin-B (Fungizone) (Invitrogen Life Technologies, 
Carlsbad, CA, USA) and 10 mM HEPES in a humidified incubator (37°C, 5% 
CO2). Cells were grown in adherent monolayer, were harvested with trypsin 
(0.05 %) and resuspended in culture medium. Cell viability always exceeded 
95%. Media and supplements were obtained from Sigma Aldrich (Sigma-
Aldrich Customer Support St. Louis, MO United States). 
 
 
3.3 Drugs and reagents  
 
 
SST  analog pasireotide (SOM230) was obtained by Novartis Pharma AG 
(Novartis, Basel, Switzerland). Octreotide was purchased from Italfarmaco 
(ITALFARMACO, Milano, Italy). Vemurafenib (PLX4032, RG7204) was 
acquired by Selleckchem (Selleckchem.com Houston, USA). Pasireotide and 
vemurafenib were diluted in  culture medium before use. Both drugs were used 
as a stock solution of 1nM (10-3M) in sterile water, PBS and dimethyl sulfoxide 
(DMSO) 100% respectively.  Anti-SSTR1 was kindly provided by Drs Herbert 
Schmid of Novartis AG (Basel, Switzerland), SSTR2-neutralizing antibody 
(UMB1) was purchased from Epitomics (abcam Inc. Cambridge, MA, USA) 
and SSTR5- neutralizing antibody (UMB4) was obtained by rabMAbs (abcam 
Inc. Cambridge, MA, USA).  
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3.4 RNA isolation and RT-qPCR 
 
 
mRNA of melanoma cell lines, HMCB, A375, M14 and COLO38 was 
isolated by Dynabeads Oligo (dt)25 kit (Dynal AS, Oslo, Norway). The poly 
(A+) mRNA was eluted in H2O (65°C) for 2 minutes twice. Twenty μl of 
cDNA were obtained in a Tris buffer (50mM, Tris-HCL ph 8.3) containing 
100 mM DTT and 10 nM MgCl2, 10 units RNase inhibitor, 2 units avian 
myelobastosis virus Super Reverse Transcriptase, oligo-dT (5 ng/ml) and 1 
mM of each deoxinucleotide triphosphate in a final volume of 40 µl. After 
an incubation of 1 h at 42°C, the resulting cDNA was gently resuspended by 
pipetting and 160 µl of sterile H2O were added. cDNA was used for 
quantification of mRNA levels of all investigated genes: B-actin, SSTR1, 
SSTR2, SSTR3, SSTR5. The primer sequences are shown in Table 1. All 
primers were purchase from Eurogentec (Eurogentec, 
Seraing, Liège, Belgium). RT-qPCR was performed by using Syber Green 
supermix (Maxima SYBR Green qPCR Master Mixes, Thermo Fisher 
Scientific Inc. Waltham MA), iCicling iQ5 (Bio-Rad Laboratories 
Headquarters 1000 Alfred Nobel Drive Hercules, CA) and iCycler iQ 
Optical System software 3.0 for real time amplification, according to the 
manufacturer’s protocol. PCRs were carried out in a final volume of 12 μl, 
containing 1μM of primers, 1X Syber Green Mix and 5 μl of RT products. 
Newly synthesized cDNAs were screened for the expression of SSTR 
subtypes (SSTR1, SSTR2, SSTR3 and SSTR5). RT-qPCR cycling 
conditions: after an initial heating at 50°C and 94° C for 5 min, samples 
were subjected to 40 cycles of denaturation (94° C for 1 min), annealing 
(59° C for 2 min) and amplification (72° C for 1 min). Samples were 
normalized against the expression of the housekeeping gene β-actin. 
Reactions lacking reverse-transcriptase enzyme were used as control for 
genomic DNA contamination. Control reaction without cDNA was used to 
confirm lack of exogenous DNA contamination. 
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GENE PRIMERS 
 
SSTR1 
 
Forward 5’-TGAGTCAGCTGTCGGTCATC-3’ 
Reverse 5’-ACACTGTAGGCACGGCTCTT-3’ 
 
 
SSTR2 
 
Forward 5’-TCGGCCAAGTGGAGGAGAC-3’ 
Reverse 5’-AGAGACTCCCCACACAGCCA-3’ 
 
 
SSTR3 
 
 
Forward 5’-CTGGGTAACTCGCTGGTCATCTA-3’ 
Reverse 5’-AGCGCCAGGTTGAGGATGTA-3’ 
 
 
SSTR5 
 
Forward 5’-CATCCTCTCCTACGCCAACAG-
3’ 
Reverse 5’-GGAAGCTCTGGCGGAAGTT-3’ 
 
 
β-actin 
 
Forward 5’-AAACTGGAACGGTGAAGGTG-3’ 
Reverse 5’TCAAGTTGGGGGACAAAAAG-3’ 
 
Tab 1. Primer sequences of SSTR1, SSTR2, SSTR3, SSTR5 and β-actin. 
 
3.5 Immunocytochemistry (ICC)  
 
 
The expression of SSTRs proteins in human melanoma cell lines was 
evaluated by ICC. Glass microslides were placed in Petri dishes (BD 
FalconTM Dish 100 x10 mm) and were coated for 30 minutes at 37°C with 
poly-lysine. A375, HMCB, M14 and COLO38 melanoma cells were plated 
on top of the prepared microslides at subconfluent concentration. After 24 
hours, medium was removed and cells were fixed with 4% 
paraformaldehyde and 0.2% picric acid in phosphate buffer, pH 6.9, for 40 
minutes at room temperature (RT). After washing in PBS, cells were treated 
for 3 minutes with 50% methanol and for 3 minutes with 100% methanol. 
After another wash (1X TRIS /HCL/Tween 0,5%), the cells were treated 
with a 3% H2O2–PBS solution for 15 minutes at RT in the dark to quench 
endogenous peroxidase. After washing, cells were incubated at 4°C over 
night (ON) with  SSTR1, SSTR2 and SSTR5 monoclonal antibodies 
(respective dilutions: SSTR1-SSTR2 1:1500, SSTR5 1:500 in antibody 
diluents (Biorbyt LLC, San Francisco, California, United States). The day 
after, the cells were incubated for 30 minutes at RT with HRP/anti-
Rabbit/Mouse (Dako, Denmark). Bound antibodies were visualized by 
incubation with freshly prepared DAB (diaminobenzidine tetrahdrochloride) 
(Dako, Denmark). Slides were counterstained with hematoxylin and 
coverslipped. For negative controls, the primary antibody was omitted. The 
cells were observed under an inverted light field microscope (Leica DMIL) 
and the images were captured at 40x magnification with a Leica DFC 240 
photo camera and LAS V 3.7 software. 
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3.6 MTT cell viability assay 
 
 
In A375, HMCB, M14 and COLO38 melanoma cells, the effects of 
vemurafenib, octreotide and pasireotide on inhibition of cell viability was 
determined by MTT assay 3-(4,5 dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium) (Sigma-Aldrich Customer Support St. Louis, MO 
United States) according to the protocol provided by the manufacturer. Cells 
were plated in 100 µl medium supplemented with 10% FBS (complete 
growth medium) in 96-well plates (8000 cells/well). Cells were incubated at 
37° C in a humidified 5% CO2 atmosphere for 24 hours to allow full 
adhesion. After 24 hours, the medium was changed with serum-free medium 
for 12 hours, in order to synchronize melanoma cells to G1 phase of cell 
cycle. After 48 hours from seeding, cells were treated once with serial 
concentrations of vemurafenib (10-14M to 10-6M) and daily with serial 
concentrations of octreotide and pasireotide (10-13M to 10-6M) in complete 
medium. In brief, at the end of treatment (72 hours), 10 µl of MTT solution 
(MTT 5mg/ml in PBS) were added to each well and incubated at 37°C for 1 
hour. MTT is a yellowish solution and it is converted to water insoluble 
MTT-formazan of dark blue color by mitochondrial dehydrogenases of 
viable cells.  The  blue formazan crystals in viable cells were solubilized in 
100 µl/well of MTT solvent (10% HCl 1N in Isopropyl alcohol). The 
intensity of color in each well was quantified as optical density (OD) at 570 
nm wavelength using Victor multi-plate reader (Victor 4X, Perkin Elmer, 
Massachusetts, USA). The percentage of cell viability inhibition in drug-
treated cultured cells against the untreated control cells was calculated as 
follow: 
 
 Inhibition (%):  (drug-treated - untreated)/untreated*100  
The experiments were repeated three times, and each experiment was 
performed in quadruplicate. 
 
 
3.7 Measurement of total DNA content: DNA assay 
 
 
A375 and M14 melanoma cells were harvested with trypsin and 25000 
cells/well were seeded in 1 ml of complete culture medium (10% FBS) in  
24-well plates. The plates were then placed in incubator in 5% CO2 at 37°C. 
After 24 hours, the complete medium was removed and the cells were 
starved with 1 ml of serum-free medium for 12 hours. After 48 hours from 
seeding cells were treated once with vemurafenib or daily with  serial 
concentrations of octreotide and pasireotide (10-10M to 10-6M) in complete 
medium for 72 hours. After 72 hours of treatment, the medium was 
discarded and cells were harvested for DNA measurement. Measurement of 
total DNA content, representative of the number of cells, was performed 
using the bisbenzimide fluorescent dye (Hoechst 33258) (Boehring 
Diagnostics, La Jolla, CA), as previously described (De Martino MC et al. 
2012). Data are expressed as percent of the control. The experiments were 
repeated three times and each experiment was performed in quadruplicate. 
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3.8 Analysis of cell cycle by flow cytometry: FACS  
 
 
Evaluation of A375 and M14 melanoma cell cycle distribution was done 
using flow cytometry. Cells were seeded in 6-well plates at density of 5 x 
104 and 15 x 104 cells respectively for A375 and M14 cell lines. After 24 
hours, the complete medium was removed and the cells were starved with 1 
ml of serum-free medium for 12 hours. Cells were then treated for 24 hours 
with vemurafenib, octreotide, pasireotide and a combination of vemurafenib 
and pasireotide. At the end of treatment cells were harvested and counted, 
then washed in PBS and stained with 50µg/ml propidium iodide for 60 min 
at RT. Possible double-stranded RNA was removed by incubation with 0.1 
mg/ml RNAse (Invitrogen Life Technologies, Carlsbad, CA, USA). 
Untreated control cells were included. Flow cytometry analysis of the cell 
cycle was carried out immediately after staining. Cells were analysed by 
flow cytometry (FACScan, Becton Dickinson, San Josè, CA, USA) using 
the CyCLOPS Summit 3.1 (Cytomation, Fort Collins, CO, USA). 
Distribution of cells in the different cell cycle phases was evaluated by Mod 
Fit 2.0 (Verity Software HOUSe INC., Ranger, ME, USA). Each 
experiment was performed three times. Changes in cell cycle distribution 
after treatment with drugs are shown as mean ± SD of cells in the different 
cell cycle phases plotted.   
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Results 
 
 
 
4.1 Expression of SSTRs in human cutaneous melanoma cell lines by RT-
qPCR 
 
 
Relative quantification for SSTRs mRNAs compared to the β-actin housekeeping gene 
expression, showed as mean± SD ) was: SSTR1 32.5±1.1 and 33.7±2.7, SSTR2: 
27±0.6 and 30.5±1.8, SSTR3: 31±2.9 and 34.4±1.1, SSTR5: 29±2 and  35.2±0.9, β-
actin: 15±0.9 and 18.2±1.2 in A375 and HMCB cells respectively. In COLO38 and 
M14 cell lines, the SSTR1 expression was 32.1±2.9 and 30.5±2, SSTR2: 27.5±3.2 and 
27.4±2.6, SSTR3: 29.3±4.4 and 29.1±2.9, SSTR5: 30.8±2.2 and 30±2.5, respectively 
(Fig.12). β-actin: 17.2±1.6 and 18.5±1.5 for M14 and COLO38 cell lines respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. RT-qPCR expression of SSTRs in melanoma cell lines (HMCB, A375, 
COLO38 and M14).Values represent mean and SEM per gene assayed in duplicate in 
three independent experiments. Expression level are normalized against the 
housekeeping gene β-actin. All values are expressed as Log 10 scale. 
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4.2 Protein expression of SSTRs in melanoma cell lines by ICC 
 
 
The protein expression and localization of SSTRs subtypes were evaluated by ICC. In 
particular, SSTR1, SSTR2 and SSTR5 expression was confirmed in all  melanoma cell 
lines. A significant amount of staining was seen within the cytoplasm and in 
perinuclear region in all melanoma cell line tested (Fig.13). SSTRs are localized 
predominantly in cytoplasm at the condition tested. Particularly, a perinucear amount 
of staining for SSTR2 in COLO38 cells and for SSTR5 in HMCB and COLO38 cells  
was detected. SSTR1 seems to be present with a similar positivity in four melanoma 
cell lines, the staining for SSTR2 is stronger in HMCB and COLO38 melanoma cells 
than others two cell lines. SSTR5 is stronger in A375 and M14 melanoma cells than 
others two cell lines. The cells were scored based on the intensity of the staining. In 
particular, a score of +++, ++, + and 0 was assigned for strong, moderate, mild and no 
staining, respectively (Tab.2). (Gatto F. et al. 2013). As positive for STTR1, SSTR2 
and SSTR5 control bronchial carcinoid H272 cells and hepatocellular carcinoma were 
used, respectively (Fig. 14). Negative control (Fig.15).  
 
 
 
 
Table 2. ICC Score of melanoma cells based on the intensity of staining. SSTR1: 
A375 strong (+++), HMCB moderate (++), COLO38 strong (+++), M14 strong (+++); 
SSTR2: A375 mild (+), HMCB moderate (++), COLO38 mild (+), M14 strong (+++); 
SSTR5: A375 strong (+++), HMCB moderate (++), COLO38 mild (+), M14 strong 
(+++).          
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Figure  13.  ICC for SSTR1, SSTR2 and SSTR5 in melanoma cell lines. 1-4 SSTR1 
in A375, HMCB, COLO38 and M14 cell lines; 5-8 SSTR2 in A375, HMCB, COLO38 
and M14 cell lines; 9-12 SSTR5 in A375, HMCB, COLO38 and M14 cell lines. 
 
 
 
 
 
 
Figure 14.  ICC for SSTR1, SSTR2 in bronchial carcinoid (H727) and SSTR5 in 
hepatocellular carcinoma (HepG2) cell lines. 1-2 SSTR1 and SSTR2 in H727 cell line. 
3 SSTR5 in HepG2 cells. H727 and HepG2 cells were used as positive control for 
SSTR1, SSTR2 and SSTR5 expression. 
 
 
 
 
 
 
Figure 15. Negative control for SSTRs in A375, HMCB, COLO38 and M14 
melanoma cell lines by ICC (1-2-3-4). Negative control refers to control in which the 
cells were incubated with antibody diluent, without the primary antibody included. 
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4.3 Effect of pasireotide on cell viability in melanoma cell lines 
 
 
In melanoma cell lines, pasireotide showed different effects on cell viability. In 
particular, daily administration of pasireotide inhibited A375 and M14 viability at all 
tested concentrations: a significant maximal inhibition was achieved at 10-7M (41% 
p<0.001 and 44% p<0.001 vs control for A375 and M14 cells, respectively) (Fig.16). 
Conversely, in COLO38 and HMCB cell lines pasireotide showed no effect on 
viability inhibition (Fig.17). 
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Figure 16. Inhibition of cell viability after 72 hours of daily incubation with serial 
concentrations of pasireotide in A375 and M14 melanoma cell lines. The histograms 
show the percentage of viability inhibition relative to control cell viability measured 
using MTT assay. The values represent the mean±SEM in quadruplicate of three 
different experiments. Control is set as 100%. 
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Figure 17. Inhibition of cell viability after 72 hours of daily incubation with serial 
concentrations of pasireotide in HMCB and COLO38 melanoma cell lines. The 
histograms show the percentage of viability inhibition relative to control cell viability 
measured using MTT assay. The values represent the mean±SEM in quadruplicate of 
three different experiments. Control is set as 100%.  
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4.4 Effect of octreotide on cell viability in melanoma cell lines 
 
 
In melanoma cell lines, octreotide showed different effects on cell viability. In 
particular, daily administration of octreotide inhibited A375 viability: a significant 
maximal inhibition was achieved at 10-6M (54.15% p<0.001 vs control) after 72 hours 
of treatment (IC50 of 2.91*10-11M) In M14 cell line the highest inhibitory response was 
observed after 72 hours of daily administration of octreotide 10-8M and IC 50 of 
7.768*10-11M (Fig.18).  Conversely, in COLO38 and HMCB cell lines octreotide 
showed no effect on viability inhibition at any of the tested drug concentrations 
(Fig.19). 
 
 
 
 
 
 
 
 
 
47 
 
A375
co
ntr
ol M
-
13
 
 
10
M
-
12
10
M
-
11
10
M
-
10
 
10
M
-
9
 
10
M
-
8
10
M
-
7
10
M
-
6
 
 
10
0
25
50
75
100
125
150
*
** **
***
***p<0.001
**p<0.01
*p<0.05
log [Octreotide] (M)
%
 
v
ia
bi
lit
y
M14
co
ntr
ol M
-
13
 
 
10
M
-
12
10
M
-
11
 
10
M
-
10
 
 
10
M
-
9
 
10
M
-
8
 
10
M
-
7
 
10
M
-
6
 
10
0
25
50
75
100
125
150
*
*p<0,05
log [Octreotide] (M)
%
 
v
ia
bi
lit
y
 
Fig 18. Inhibition of cell viability after 72 hours of daily incubation with serial 
concentrations of octreotide in cutaneous melanoma cell lines (A375 and M14). The 
histograms show the percentage of viability inhibition relative to control cell viability 
measured using MTT assay. The values represent the mean±SEM in quadruplicate of 
three different experiments. Control is set as 100%.  
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Figure 19. Inhibition of cell viability after 72 hours of daily incubation with serial 
concentrations of octreotide in malignant melanoma cell lines (HMCB and COLO38). 
The histograms show the percentage of viability inhibition relative to control cell 
viability measured using MTT assay. The values represent the mean±SEM in 
quadruplicate of three different experiments. Control is set as 100%.   
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4.5 Effect of vemurafenib on cell viability in melanoma cell lines 
 
 
Vemurafenib showed different effects on cell viability  in melanoma cell lines. (Fig.20 
and Fig 21 .The graphs show the effects of vemurafenib in A375, M14, HMCB and 
COLO38 melanoma cell lines). In particular, in A375 cell line vemurafenib 
significantly suppressed the cell viability in a dose and time-dependent manner. The 
A375 cell viability is significantly inhibited at the maximal concentration tested (10-
6M) (55.52%, 65.52%, 82.89%, p< 0.001 vs control) after 24, 48 and 72 hours of 
treatment respectively, with IC50 of 10-8M at all time of treatment assayed. In HMCB 
cell line, vemurafenib is able to significantly inhibit cell viability at the maximal 
concentration tested (10-6M) (44.31%, p<0.001, 37.16%, p<0.01, 36.05%, p<0.01 vs 
control) after 24, 48 and 72 hours of treatment respectively, with IC50 of 9.2*10-12M, 
5*10-13M and 3.2*10-12M after the different times of treatment. In M14 cell line the 
highest inhibitory response was observed after 72 hours of treatment and with the 
highest concentration of vemurafenib (10-6M), with a mean inhibition of viability of 
29.97% (IC50 of 4.33*10-8M). In COLO38 cell line, the maximal inhibition of cell 
viability was achieved with 10-6M of vemurafenib (42.08% vs control) after 48 hours 
of treatment with IC50 of 1.33*10-7M. In M14 and COLO38 cell lines the inhibition 
of cell viability observed after treatment with vemurafenib was not statistically 
significant.  
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Figure 20.  Effect of vemurafenib on melanoma cell lines viability (A375, M14) by 
MTT assay. Data are expressed as the percentage of control and represent the 
mean±SEM. The maximal significant inhibition was achieved with vemurafenib 10-6M 
(55.52%, 65.52%, 82.89%, p< 0.001 vs control in A375 cells). In M14 cell line 
vemurafenib inhibited the cell viability only at 10-6M (29.97%). Control is set as 
100%. ***P<0.001, **P<0.01, *P<0.05. 
 
 
 
 
51 
 
 HMCB
-14 -13 -12 -11 -10 -9 -8 -7 -6
0
25
50
75
100
125
150
C
24h
48h
72h
log [Vemurafenib] (M)
%
 
o
f v
ia
bi
lit
y
 
 
COLO38
-14 -13 -12 -11 -10 -9 -8 -7 -6
0
25
50
75
100
125
150
C
24h
48h
72h
log [Vemurafenib] (M)
%
 
v
ia
bi
lit
y
 
Figure 21.  Effect of vemurafenib on melanoma cell lines viability (HMCB and 
COLO38) by MTT assay. Data are expressed as the percentage of control and 
represent the mean±SEM. In HMCB cell line, vemurafenib is able to significantly 
inhibit the cell viability with the maximal concentration tested (10-6 M) (44.31%, 
p<0.001, 37.16%, p<0.01, 36.05%, p<0.01 vs control) after 24, 48 and 72 hours of 
treatment respectively. In COLO38 cell line, the maximal inhibition of cell viability 
was achieved with 10-6 M of vemurafenib (42.08% vs control) after 48 hours of 
treatment. Control is set as 100%. ***P<0.001, **P<0.01, *P<0.05.  
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4.6 Effect of combined treatment with vemurafenib and pasireotide on cell 
viability in melanoma cell lines 
 
 
Combined treatment with pasireotide and vemurafenib showed different effects on cell 
viability of four melanoma cell lines. In particular, in A375 cell line, the combined 
treatment with vemurafenib and daily administration of pasireotide for 72 hours of 
treatment significantly inhibited the cell viability vs control (vemurafenib 10-8M + 
pasireotide 10-13M 36.3% p<0.001, vemurafenib 10-8M + pasireotide 10-11M 41.77% 
p<0.001, vemurafenib 10-8M + pasireotide 10-9M 41.79% p>0.001, vemurafenib 10-8M 
+ pasireotide 10-7M 27.62% p<0.01). Pasireotide 10-7M was able to significantly 
inhibit the cell viability (29.97% p<0.001 vs control). The combined treatment with 
vemurafenib and pasireotide showed a significant suppression of cell viability at all 
tested concentrations except for pasireotide 10-7M vs vemurafenib 10-8M (vemurafenib 
10-8 M + pasireotide 10-13 M 24.48% p<0.01, vemurafenib 10-8 M + pasireotide 10-11 
M 29.33% p<0.001, vemurafenib 10-8 M + pasireotide 10-9 M 34.19% p<0.001) and vs 
pasireotide (pasireotide 10-13M vs vemurafenib 10-8 M + pasireotide 10-13 M 36.64% 
p<0.001, pasireotide 10-11 M vs vemurafenib 10-8 M + pasireotide 10-11 M 36.58% 
p<0.001, pasireotide 10-9 M vs vemurafenib 10-8 M + pasireotide 10-9 M 28.56% 
p<0.001). In M14, HMCB and COLO38 melanoma cell lines, combined treatment 
with vemurafenib and pasireotide induced only a moderate inhibition of cell viability 
at all tested concentration. This inhibition did not, however, exceeded 50% of the 
control proliferation under any conditions (Fig.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 A375
co
ntr
ol M-8
V 1
0 M
 
-
13
P 1
0
M
-
13
M 
+ 
P 1
0
-
8
V 1
0
 
M 
-
11
P 1
0
M
-
11
M+
 
P 1
0
-
8
V 1
0
M 
-
9 
P 1
0
M
-
9
M 
+P
 
10
-
8
V 1
0
 
M 
-
7
P 1
0
M
-
7
M 
+ 
P 1
0
-
8
V 1
0
0
25
50
75
100
125
150
***
***
***
**
*** p<0.001
**  p<0.01
%
 
v
ia
bi
lit
y
 
  M14
co
ntr
ol M-8
V 1
0 M
 
-
13
P 1
0
M
-
13
M 
+ 
P 1
0
-
8
V 1
0
 
M 
-
11
P 1
0
M
-
11
M 
+ 
P 1
0
-
8
V 1
0
 
M 
-
9
P 1
0
M
-
9
M 
+P
 
10
-
8
V 1
0
 
M 
-
7
P 1
0
M
-
7
M 
+P
 
10
-
8
V 1
0
0
25
50
75
100
125
150
%
 
v
ia
bi
lit
y
 
 
 
54 
 
COLO38
co
ntr
ol M-8
V 1
0 M
 
-
13
P 1
0
M
-
13
M 
+ 
P 1
0
-
8
V 1
0
 
M 
-
11
P 1
0
M
-
11
M+
 
P 1
0
-
8
V 1
0
M 
-
9 
P 1
0
M
-
9
M 
+P
 
10
-
8
V 1
0
 
M 
-
7
P 1
0
M
-
7
M 
+ 
P 1
0
-
8
V 1
0
0
25
50
75
100
125
150
%
 
v
ia
bi
lit
y
 
 
HMCB
co
ntr
ol M-8
V 1
0 M
 
-
13
P 1
0
M
-
13
M 
+ 
P 1
0
-
8
V 1
0
 
M 
-
11
P 1
0
M
-
11
M+
 
P 1
0
-
8
V 1
0
M 
-
9 
P 1
0
M
-
9
M 
+P
 
10
-
8
V 1
0
 
M 
-
7
P 1
0
M
-
7
M 
+ 
P 1
0
-
8
V 1
0
0
25
50
75
100
125
150
%
 
v
ia
bi
lit
y
 
Figure 22. Effect on melanoma cell lines viability (A375, M14, COLO38 and HMCB) 
after 72 hours of treatment with vemurafenib and pasireotide in combination (MTT 
Assay). Pasireotide was administrated every day. Data are expressed as the percentage 
of control and represent the mean±SEM of three different experiments in 
quadruplicate. Control is set as 100%.   
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4.7 Effect of pasireotide on melanoma cell lines proliferation 
 
 
The daily administration of pasireotide for 72 hours in melanoma cell lines A375 and 
M14 was able to inhibit cell proliferation in a dose-dependent manner. In A375 cells 
the maximal significant inhibition of cell proliferation, was achieved with pasireotide 
10-7M and 10-6M (18.32% and 20.57% p<0.05 vs control, respectively), as measured 
by DNA assay( Fig.23). Also in M14 cells pasireotide significantly suppressed cell 
proliferation at the concentration of 10-7M and 10-6M (23.51% and 21.02% p<0.05 vs 
control, respectively) (Fig.24). 
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Figure 23. Effect of daily administration of pasireotide for 72 hours on melanoma cell 
lines proliferation in A375 melanoma cells. Data are expressed as the percentage of 
control and represent the mean±SEM. Control is set as 100%. Images under the graph 
represent A375 cells treated for 72 hours with serial concentrations of pasireotide (10-
10M -10-6M). The pictures are acquired at 10X magnification. 
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Figure 24. Effect of daily administration of pasireotide for 72 hours on melanoma cell 
lines proliferation in M14 melanoma cells. Data are expressed as the percentage of 
control and represent the mean±SEM. Control is set as 100%. Images under the graph 
represent M14 cells treated for 72 hours with serial concentrations of pasireotide (10-
10M -10-6M). The pictures are acquired at 10X magnification. 
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4.8 Effect of octreotide on melanoma cell line proliferation 
 
 
In melanoma cell lines the SST analog octreotide did not show any effect on cell 
proliferation. The cell proliferation of A375 and M14 melanoma cells line was not 
inhibited by daily treatment with serial concentration of octreotide (10-10M-10-6M) for 
72 hours (Fig.25 and Fig.26) 
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Figure 25. Effect of octreotide on A375 cell line proliferation by DNA assay. Data are 
expressed as the percentage of control and represent the mean±SEM of three different 
experiments in quadruplicate. Control was set as 100%. Images under the graph 
represent A375 cells treated for 72 hours with serial concentrations of octreotide (10-
10M -10-6M). The pictures are acquired at 10X magnification. 
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Figure 26. Effect of octreotide on M14 cell line proliferation by DNA assay. Data are 
expressed as the percentage of control and represent the mean±SEM of three different 
experiments in quadruplicate. Control was set as 100%. Images under the graph 
represent A375 cells treated for 72 hours with serial concentrations of octreotide (10-
10M -10-6M). The pictures are acquired at 10X magnification. 
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4.9 Effect of vemurafenib on melanoma cell lines proliferation  
 
 
In melanoma cell lines, vemurafenib showed different effects on  cell proliferation. 
Treatment of A375 with vemurafenib for 72 hours achieved a significant inhibition of 
cell proliferation with vemurafenib at 10-8M, 10-7M and 10-6M (18.97%, 30.81% and 
33.06% vs control p<0.001) as measured by DNA assay (Fig.27). In M14 cell line 
vemurafenib induced a inhibition of cell proliferation only at 10-6M concentration 
(15.26% vs control p<0.01) (Fig.28). 
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Figure 27.  Effect of vemurafenib on A375 cell line proliferation by DNA assay. Data 
are expressed as the percentage of control and represent the mean±SEM of three 
different experiments in quadruplicate. Control was set as 100%. Images under the 
graph represent A375 cells treated for 72 hours with serial concentrations of 
Vemurafenib (10-10M -10-6M). The pictures are acquired at 10X magnification.  
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Figure 28. Effect of vemurafenib on M14 cell line proliferation by DNA assay. Data 
are expressed as the percentage of control and represent the mean±SEM of three 
different experiments in quadruplicate. Control was set as 100%. Images under the 
graph represent M14 cells treated for 72 hours with serial concentrations of 
Vemurafenib (10-10M -10-6M). The pictures are acquired at 10X magnification. 
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4.9 Effect of combined treatment with vemurafenib and pasireotide on 
melanoma cell line proliferation  
 
 
Combined treatment with pasireotide + vemurafenib did not show additive effects on 
cell proliferation, as measured by DNA assay, compared to the single treatment with 
each drug in A375 and M14  melanoma cell lines (Fig. 29) In particular, the combined 
treatment with vemurafenib and pasireotide administered daily, for 72 hours, was not 
able to increase the inhibitory effect on melanoma cell proliferation in A375 and M14 
cells compared to  vemurafenib and pasireotide. Both single treatment and 
combination of vemurafenib and pasireotide (10-8M) were only able to inhibit 
significantly cell proliferation compared to control (13.16% p< 0.01, 39.76% p<0.01 
and 16.22% p<0.01 vs control for pasireotide, vemurafenib and vemurafenib + 
pasireotide, respectively in A375 cells; 14.88% p<0.001, 19.84% p<0.001 and 15.64% 
p<0.001 vs control for vemurafenib, pasireotide and vemurafenib + pasireotide, 
respectively in M14 cells). 
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Figure 29. Effect on melanoma cell lines proliferation (A375 and M14) of 72 hours of 
combined treatment with vemurafenib and pasireotide at a concentration of 10-8M 
(DNA Assay). Pasireotide was administrated every day. Data are expressed as the 
percentage of control and represent the mean±SEM. Control is set as 100%. Images 
under the graphs represent A375 and M14 cells respectively, treated for 72 hours with 
serial concentration of combined treatment with vemurafenib and pasireotide (in 
control and pasireotide 10-8M, DMSO was added as vehicle). The pictures are 
acquired at 10X magnification. 
 
64 
 
4.10 Analysis of cell cycle by FACS 
 
 
To determine whether the observed effects on cell viability and proliferation were  
elicited by gross changes in cell cycle progression such as cell cycle phase blocks, 
treated and untreated cells (A375 and M14) were stained with propidium iodide (PI) 
following a 24 hours incubation with pasireotide, vemurafenib and the combination of 
them. All drugs are used at the concentration of 10-8M. The staining with PI offers an 
instantaneous depiction of cell cycle. Flow cytometry analysis revealed that: in A375 
cells, treatment with pasireotide induced a moderate reduction of cells % in G2/M 
phase compared to untreated cells after 24 hour of treatment, vemurafenib induced an 
increase of cells % in G0-G1 phase and the combined with psireotide and vemurafenib 
treatment determinate a reduction of cells % in phase S (Fig.30). In M14 cells, 
treatment with pasireotide induced a moderate reduction of cells % in G2/M phase, 
vemurafenib strongly increase the cells % in G0-G1, moderate reduced the cells % in 
G2/M and strongly reduced the cells in % S phase. The combined treatment  with 
pasireotide and vemurafenib induced a reduction of cells % in G2/M and S pahases 
(Fig.31). The following tables summarize the cells % distribution  of cells in cell cycle 
phases after 24 hour of treatment  with each compounds. (Tab.3 and Tab.4 for A375 
and M14 cells, respectively). No big alterations of the cells cycle was detected after 
treatment, but a strong decrease of the number of treated cells suggest a anti-
proliferative effects of tested compounds.  
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Figure 30. Analysis of A375 cell cycle by FACS. A375 cells are treated with 
pasireotide, vemurafenib and pasireotide+vemurafenib at dose of 10-8M for 24 hour. 
M14 ells were stained with Propidium iodide (PI) (50µg/µl). 
 
 
 
 
Table 3. Table summarizes the relative distribution of A375 cells (%) in the different 
phases of the cell cycle after 24 hours of treatment with pasireotide, vemurafenib and 
pasireotide + vemurafenib. All tested drugs are at the concentration of 10-8M. 
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Figure 31. Analysis of M14 cell cycle by FACS. M14 cells were treated with 
pasireotide, vemurafenib and pasireotide+vemurafenib at dose of 10-8M for 24 hour. 
M14 ells were stained with Propidium iodide (PI) (50µg/µl). 
 
 
 
Table 4. Table summarizes the relative distribution of M14 cells (%) in the different 
phases of the cell cycle after 24 hours of treatment with pasireotide, vemurafenib and 
pasireotide + vemurafenib. All tested drugs are at the concentration of 10-8M. 
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Discussion 
 
This study shows that four different types of human cutaneous melanoma cell 
lines have different mRNA and protein expression pattern of SSTRs. In two of 
these cell lines, treatment with SST analogs, particularly pasireotide a multi-
ligand receptors, inhibits cell viability and proliferation in a concentration-
dependent manner.  
CMM remains a devastating disease with poor prognosis, despite the great 
efforts to develop new treatments and to understand the molecular mechanisms 
underlying its oncogenesis and progression. The median survival time for 
patients with metastatic melanoma is 8-9 months, and the 3-year-survival rate 
is less than 15 percent (Balch CM. et al. 2009). The incidence and mortality of 
CMM, in contrast to many other tumor types, continues to increase worldwide. 
Surgical resection remains the mainstay of therapy for localized disease, 
whereas new treatment options are required for CMM. Molecular targeted 
therapies have been promisingly developed during the last years to improve the 
response rate, to reduce the adverse effects and toxicity and to overcome the 
onset of resistance to the current antineoplastic therapies. The understanding of 
the driven genetic aberrations in melanoma has allowed the development of 
new treatment approach for patients with this malignancy. Nevertheless these 
molecular targeted therapies are predicted to be effective only in a subset of 
patients, that are generally those presenting the appropriate alteration in the 
molecular targets and not presenting any activated mechanism of resistance 
(Arnedos M. et al. 2014). Additionally after a certain time, also responsive 
patients can develop resistance, rising the requirement of new alternative 
therapeutic strategies. In the field of new therapeutic approaches, the 
introduction of SST analogs represents an attractive perspective because of 
SST ability to control hormonal secretion and inhibit progression in 
neuroendocrine tumors (Ruscica M. et al. 2013). The expression of  membrane 
receptors in several tumors represent an interesting option for target therapy 
also because these receptors after ligand binding can be internalized thus they 
can carry into tumor cells radionuclide-conjugated or chemotherapeutic-
conjugated ligands. The use of radionuclides-conjugated SST analogs in 
patients with neuroendocrine tumors testify the role of SSTRs in diagnosis and 
treatment of human neoplasia. The role of SSTRs in cutaneous melanoma has 
been scantily described. Indeed only few studies evaluated SSTRs expression 
in human samples, the role of radionuclides-conjugated SST scintigraphy and 
SST analog treatment in melanoma. Octreotide most clinically developed SST 
analog, has an higher affinity for SSTR2. SSTR2 is abundantly expressed in 
cutaneous melanoma as well as in other tumor types including neuroendocrine 
tumors (Hofland L. and S.W. Lamberts. 2001, Lum SS et al. 2001). Lum SS. et 
al. showed by RT-PCR and Southern blotting that SSTR1-2-3-4-5 are 
expressed in 96%, 83%, 61%, 57% and 9%, respectively, in malignant 
melanoma biopsies from 17 patients. Moreover, they demonstrated that 111In-
Pentetreotide scintigraphy (OctreoScan) was able to successfully image 63% of 
melanomas in a subgroup of evaluated patients. According to Martinez Alonso 
et al., SSTR2 mRNA is the predominant SSTR mRNA expressed in 18 skin 
melanoma cell lines including 4 primary tumor-derived and 14 metastatic 
tumors-derived (12 cutaneous and subcutaneous and 2 visceral). They observed 
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that all melanoma cell lines express the mRNA of at least one of the four 
SSTRs. The majority of cell lines express at the highest levels  SSTR2, 
followed by SSTR1, SSTR3 and SSTR5. The current study confirms by 
relative mRNA quantification of SSTRs, that SSTR2 is the highest expressed 
SSTR subtype in four melanoma cell lines (A375, HMCB, M14 and COLO38). 
However, the relative expression of the other SSTR investigated was different 
compared with previous reports being mRNA levels of  SSTR5 and  SSTR3 
higher than SSTR1 in three of the four evaluated cell lines. Taking in account 
that the melanoma cell lines tested in our study are different from those used in 
the above motioned studies, these results support the existence of an 
heterogeneous expression of SSTRs in CMM. In all cell lines the protein 
expression of SSTR1, SSTR2 and SSTR5 was confirmed by ICC. Few data are 
available about SSTRs protein expression in uveal melanoma.  Valsecchi ME. 
et al. demonstrated that 46% of patients with uveal melanoma (14 of 30 
patients) were positive by Octreoscan. IHC was performed on 10 Octreoscan-
positive patients. All of them expressed SSTR2. In another series of uveal 
melanoma the expression of SSTRs observed by IHC, was 60%, 92%, 28% and 
52% for SSTR2A, SSTR2B, SSTR3 and SSTR5, respectively. Additionally 
patients presenting an high SSTR2 protein expression levels had a better 
survival compared to those with low levels, suggesting that SSTR2 protein 
expression could be useful as marker of prognosis (Ardjomand N. et al). To 
our knowledge the current study is the first report on the  SSTR1, 2 and 5 
protein expression in preclinical model CMM. The evaluation of protein 
expression by ICC is interesting because it also suggests the protein subcellular 
localization. The present study suggests that at the condition tested, SSTRs are 
predominantly expressed in cytoplasm. SSTRs are membrane-associated 
receptors but SSTR-ligand complexes undergo cellular internalization with 
progressive translocation from the cytoplasm to the nucleus (C.A. Hornick et 
al. 2000, D.D. Klisovic et al. 2001, J.C. Reubi et al. 2001). Renzo Cescato et 
al. evaluated by IHC the SSTR2, SSTR3 and SSTR5 receptor internalization 
after agonist or antagonist treatment (R. Cescato et al. 2006). They observed 
that SSTR2 and SSTR3, in untreated cells (HEK 293, human embryonic 
kidney) are localized exclusively to the cell surface. Conversely, even in 
untreated cells SSTR5 is not only localized to cell-surface but also in 
intracellular perinuclear and cytoplasmatic regions. Furthermore, their study 
showed that SSTR2 and SSTR3 agonists, but not SSTR2 and SSTR3 
antagonists, can trigger receptor internalization. The authors suggested that 
SSTR5 intracellular distribution might depend by its particular trafficking. 
Indeed SSTR5 might either not be internalized upon ligand binding, either it 
might undergo to a rapid recycling after internalization as result of a massive 
recruitment to the cell surface from an intracellular SSTR5 reserve pool (Stroh 
T. et al. 2000). Therefore, it is possible to speculate that in untreated melanoma 
cell lines SSTRs are localized predominantly in cytoplasmatic region, but that 
at least partially after SST analogs stimulation, they might be recruited to the 
plasma membrane. To confirm this hypothesis western blotting experiments are 
ongoing (data not shown). Preliminary results shows that SSTR5 might be 
recruited to plasma membrane upon pasireotide binding suggesting that the 
different trafficking of SSTR2 and 5 might explain the stronger 
antiproliferative effects observed with pasireotide compared to octreotide in the 
two responsive melanoma cell lines. These results will clarify the different sub-
cellular distribution of SSTRs before and after SST analogs stimulation. 
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Additionally, to detect SSTR subtypes position in the different cellular 
compartments in melanoma cells, confocal and electron microscopy has also 
been planned. Tejeda M. et al. demonstrated that TT-232, a SST analog with 
high affinity for SSTR1 and SSTR4, had an anti-proliferative effects (tumor 
growth inhibition and survival time prolongation) in B-16 rodent melanoma 
and in HT-18 human lymphoid melanoma xenograft models. Schwab RE at al. 
also tested the anti-proliferative efficacy of TT-232 in human melanoma cell 
lines and tumors. They investigated the effect of TT-232 in seven melanoma 
cell lines and two xenograft CB17-SCID mice. T-232 strongly inhibited 
proliferation of all cell lines in vitro and tumor viability in vivo. Martinez-
Alonso et al. investigated the effect of SST analogs, octreotide and pasireotide, 
in 18 primary and metastatic human cutaneous melanoma cell lines. Both of 
the SST analogs inhibited melanoma cell proliferation in a concentration-
dependent manner. Both SST analogs induced only a moderate inhibition of 
melanoma cell viability (maximal inhibition observed with 10-6M after 3 days 
of treatment: 19.85% and 18.55% vs control, respectively). In the present 
study, the four melanoma cell lines used had a different sensitivity to the two 
SST analogs tested. Octreotide is a synthetic SST analog with high binding 
affinity for SSTR2. Although SSTR2 was the most expressed SSTR subtype at 
mRNA level and it was clearly expressed also at protein level in all cell lines 
tested, octreotide inhibited cell viability only in A375 and M14 cells. The 
maximal significant inhibition was achieved with 10-6M (54.15% p<0.001 and 
24.32% p<0.01 vs control; IC502.9*10-11M and 7.7 10-11M, respectively). 
Octreotide did not inhibited cell proliferation in the four melanoma cell lines 
used. Pasireotide is a novel multireceptor SST analog, which binds with high 
affinity to all SSTRs except to SSTR4 (Weckbecker G. et al. 2002). In contrast 
to octreotide, pasireotide exhibits particularly high subnanomolar affinity to 
SSTR5 (Ma P. et al. 2005). Pasireotide significantly inhibited, in a dose 
dependent-manner, viability and proliferation in two melanoma cell lines 
(A375 and M14). Both these cell lines presented a strong protein expression of 
SSTR5. Conversely, pasireotide did not have any effects in two melanoma cell 
lines (HMCB and COLO38) that had weak SSTR5 protein expression. These 
results suggest that pasiretotide might at least in part exerts is action through 
SSTR5 binding and that strong protein expression of SSTR5 could be 
predictive of response to this drug in human cutaneous melanoma cells. These 
results are in agreement with previous reports that suggest that pasireotide has 
stronger  antisecretive and antiproliferative effects than octreotide in cells and 
tissues that express SSTR5 other than the SSTR2 and 1 receptor subtype 
(Schmid HA. 2007). This is also in line with the different affinity profile of 
pasireotide and octreotide for the various SSTRs (Tab.5).  
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Table 5. Relative binding affinity of SST analogs for the five SSTRs. 
 
 
Additionally pasireotide might be stronger than octreotide because trafficking 
of SSTRs upon octreotide and pasireotide stimulation strongly differ (Cescato 
R. 2006). Some studies have suggested that Octreotide induces rapid 
internalization of SSTR2 and subsequent ß-arrestin binding and receptor 
degradation into endocytic vesicles potentially determining receptor 
desensitization (Pöll F. et al. 2010, Hipkin RW. et al. 1997). Pasireotide 
induces the recruitment of a functionally distinct pools of ß-arrestin that bind to 
SSTR2 in unstable ß-arrestin-SSTR2 complexes. Consequently, SSTR2 
recycles rapidly to the plasma membrane after endocytosis in pasireotide-
treated cells, but not in octreotide-treated cells. Compounds with high affinity 
to both SSTR2 and SSTR5, show distinct internalization properties at these 2 
receptors: a strong SSTR2 internalization and rapid recycling but no SSTR5 
internalization (Cescato R. 2006).  
In both responsive melanoma cell lines the maximal significant inhibition, with 
daily administration of pasireotide was achieved with 10-7M (about 40% for 
viability and 20% for proliferation). The IC50 of pasireotide was 8.3*10-12M 
and 5.16 *10-13M
 
in A375 and M14 cells respectively that are within the range 
of tolerability, as determined in clinical trials (Cmax about 10-7M) 
(Beglinger C. et al. 2012). The effects of pasireotide on cell viability observed 
at the tested condition were stronger than the effects on cell proliferation. In 
melanoma cell lines the different effects of octreotide and pasireotide on cell 
viability (measuring metabolic activity of cells) and proliferation (measuring 
the effective number of cells) could depend by the different techniques used 
and by the fact that the inhibition of metabolic activity is a precocious event 
that could precede the inhibition of cell proliferation. 
Preliminary results of the FACS analysis suggest that the antiproliferative 
effects of pasireotide in A375 and M14 could at least in part depend by an 
inhibition of cell cycle.   
Vemurafenib, a selective BRAF V600 mutant kinase inhibitor, was approved 
by FDA in August 2011 based on the BRIM3 Phase III study showing 
improved clinical outcomes compared to dacarbazine (Chapman PB. et al. 
2011. 2012). The objective response rate for vemurafenib was 48% after  five 
months and an overall survival of 84% after six months. It represents a major 
breakthrough in targeted therapeutics of advanced melanoma. Unfortunately, 
the benefit of this agent is limited by the frequent and rapid onset of resistance. 
Multiple mechanisms of resistance have been described, including elevated 
expression of the kinase CRAF (Montagut C. et al. 2008), activating mutations 
in N-RAS, MEK1, or AKT1 (Nazarian R. et al. 2010, Wagle N. et al. 2011, Lo 
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RS. 2012) aberrant splicing of BRAF (Poulikakos PI. et al. 2011), activation of 
phosphatidylinositol-3-OH kinase (PI3K) via the loss of PTEN (Paraiso KH. et 
al. 2011), and persistent activation of receptor tyrosine kinases, including 
platelet-derived growth factor receptor b (PDGFRb), insulin-like growth factor 
IR (IGF-IR), and EGF receptor (EGFR) (Villanueva J. et al. 2010, Girotti MR. 
et al. 2013). Since these mechanisms of resistance to monotherapy have been 
reported, recent therapeutics efforts have focused on increasing MAPK 
inhibition trough combined therapies. The RAS/RAF/MEK/ERK signaling 
pathway is central to the pathogenesis of cutaneous melanoma (McCubrey. et 
al. 2007) and for this reason it represents a primary therapeutic target. SST 
analogs also could exert their anti-proliferative effects by modulating MAPK 
signaling (Theodoropoulou M. et al. 2013). Investigating the function of each 
SSTR in several tumor types has provided a wealth of information about the 
common but also distinct signaling cascades that suppress tumor cell 
proliferation, survival and angiogenesis, this provide the rationale for 
developing multi-receptor-targeted SST and combination with signaling 
targeted agents such as BRAF inhibitors. Vemurafenib significantly inhibited 
A375 cell viability and proliferation in a time and dose dependent manner. 
These results are consistent with the well documented BRAF V600E mutation 
in A375 melanoma cell line. In HMCB twenty-four hours treatment with 
vemurafenib significantly affected cell viability at maximal concentration, but 
this effect was lost with time. In agreement with previous reports melanoma 
cells with wild-type BRAF are not responsive to vemurafenib (Poulikakos PI. et 
al 2010, Hatzivassiliou G. et al. 2010). At condition tested Vemurafenib did 
not significantly inhibit cell viability and cell proliferation in M14 and 
COLO38. The genetic background and potential mutations other than BRAF 
may affect the response to these drugs.  
In A375 the combined treatment with vemurafenib and pasireotide had 
significant additive effects on cell viability but not on cell proliferation. In M14 
combined treatment with vemurafenib and pasireotide had no significant 
additive effects on cell viability and cell proliferation. In HMCB and COLO38 
combined treatment with vemurafenib and pasireotide had no significant 
additive effects on cell viability while cell proliferation was not investigated. In 
pasireotide sensitive cells (A375 and M14), the loss of additivity may be due to 
the activation of escape pathways and/or to the capability of vemurafenib to 
affect the SSTRs trafficking.  
Taking together, the results of the current study have a potential translational 
value since the expression of SSTRs might indicate the potential use of SST 
analogs, radio-labeled SST analogs, SST analogs conjugate with 
chemotherapic agents and SSTR scintigraphy in the management of a subset of 
patients with CMM. This study encourages further studies to better define the 
role of SST pathway in diagnosis, prognosis and as potential target for 
treatment in human CMM.    
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Conclusion 
 
 
 
Our data provide evidence for SSTRs expression in CMM supporting the 
hypothesis that this tumor might have some neuroendocrine features. The pan-
SSTRs agonist pasireotide significantly inhibits cell viability and proliferation 
in two human CMM cell lines (A375 and M14), with greater effects as 
compared to octreotide. These data suggest that SST analogs, particularly 
pasireotide, may have a role in the treatment of patients with CMM. The cell 
lines responding to pasireotide present a higher protein expression of SSTR5, 
suggesting that strong SSTR5 protein expression could be predictive of 
responsiveness to this drug in CMM. Three day-treatment with vemurafenib 
significantly inhibits cell viability and cell proliferation only in one CMM cell 
line (A375) with a well characterized BRAF mutation. Combined treatment 
with vemurafenib and pasireotide do not have additive inhibitory effects in 
most of cases, suggesting that the combination of these treatments does not 
give major advantages. 
This study has a potential translational value since the expression of SSTRs 
might indicate the potential use of SST analogs, radio-labeled SST analogs, 
SST analogs conjugate with chemotherapic agents and SSTR scintigraphy in 
the management of a subset of patients with CMM. These results encourage 
further studies to better define the role of SST pathway in diagnosis and 
prognosis, and as potential target for treatment in human CMM.    
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